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Abstract 
Reprogramming somatic cells to a pluripotent state drastically reconfigures the cellular 
anabolic requirements, thus potentially inducing cancer-like metabolic transformation. 
Accordingly, we and others previously showed that somatic mitochondria and bioenergetics 
are extensively remodeled upon derivation of induced pluripotent stem cells (iPSCs), as the 
cells transit from oxidative to glycolytic metabolism. In the attempt to identify possible 
regulatory mechanisms underlying this metabolic restructuring, we investigated the 
contributing role of hypoxia-inducible factor 1 alpha (HIF1α), a master regulator of energy 
metabolism, in the induction and maintenance of pluripotency. We discovered that the 
ablation of HIF1α function in dermal fibroblasts dramatically hampers reprogramming 
efficiency, while small molecule-based activation of HIF1α significantly improves cell fate 
conversion. Transcriptional and bioenergetic analysis during reprogramming initiation 
indicated that the transduction of the four factors is sufficient to up-regulate the HIF1α target 
pyruvate dehydrogenase kinase (PDK) 1 and set in motion the glycolytic shift. However, 
additional HIF1α activation appears critical in the early up-regulation of other HIF1α-
associated metabolic regulators, including PDK3 and pyruvate kinase (PK) isoform M2 
(PKM2), resulting in increased glycolysis and enhanced reprogramming. Accordingly, 
elevated levels of PDK1, PDK3, and PKM2 and reduced PK activity could be observed in 
iPSCs and human embryonic stem cells (hESCs) in the undifferentiated state. Overall, the 
findings suggest that the early induction of HIF1α targets may be instrumental in iPSC 
derivation via the activation of a glycolytic program. These findings implicate the HIF1α 
pathway as an enabling regulator of cellular reprogramming.  
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Introduction 
Oxygen concentration plays a critical role in mediating modifications of the cellular 
metabolic profile [1]. Under physiological normoxic conditions, human somatic cells are 
characterized by active mitochondria and oxidative phosphorylation (OXPHOS)-based 
metabolism, while oxygen-deprived cells exhibit increased conversion of glucose to lactate 
(the “Pasteur effect”). However, tumor cells fine-tune their cellular bioenergetics to respond 
to higher cellular demands and can shift to glycolysis-based metabolism even in the presence 
of high level of oxygen, a phenomenon known as aerobic glycolysis or “Warburg effect” [2, 
3]. This metabolic shift seems apparently counter-intuitive given the low efficiency of 
glycolytic metabolism in terms of generation of ATP molecules. Nevertheless, several lines of 
evidence demonstrate that this metabolic adaptation endows proliferative cells with critical 
advantages.  
First, anabolic pathways branching out from the glycolytic path supply the 
intermediates for cell growth, including amino acids and lipid precursors [4, 5]. Thus, rapidly 
dividing cells, such as cancer cells, increase the flux through glycolysis to satisfy their need of 
macromolecules, by enhancing glucose uptake and by slowing the entry of pyruvate into 
mitochondria [6]. Second, the energy reconfiguration can provide protection against oxidative 
stress [5], by avoiding high levels of reactive oxygen species (ROS), common by-products of 
mitochondrial respiration, and by re-routing glycolytic intermediates into the pentose 
phosphate pathway, which generates not only essential nucleotide precursors but also the 
reducing factor NADPH, required for the activity of antioxidant enzymes [7]. Recent data on 
pyruvate kinase, which catalyzes the conversion of phosphoenolpyruvate (PEP) into pyruvate 
in the last step of the glycolytic cascade, support the idea that the Warburg effect may 
promote cellular redox homeostasis. Pyruvate kinase isoform M2 (PKM2) is highly expressed 
in cancer cells [8, 9] and upon oxidation it looses activity, thereby reducing pyruvate 
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formation and diverting the glycolytic flux into the pentose phosphate pathway, which 
eventually supports antioxidant activities [10-12].   
A key mediator of the metabolic re-configuration occurring under low oxygen 
conditions is the transcription factor hypoxia-inducible factor 1 (HIF1) [13, 14]. HIF1 is a 
heterodimer consisting of a constitutively expressed HIF1 β subunit and an oxygen-regulated 
HIF1α, which is physiologically degraded under normoxic conditions by oxygen-dependent 
prolyl-hydroxylases (PHD1-3). When oxygen level decreases, or when PHD enzymes are 
pharmacologically inhibited, HIF1α protein escapes degradation and translocates in the 
nucleus, where it initiates a gene expression reprogramming ultimately leading to a switch 
from OXPHOS to glycolysis. HIF1α target genes include glucose transporters, to increase 
glucose uptake, and pyruvate dehydrogenase kinases (PDK1-3) [15-17], to shunt pyruvate 
away from the mitochondria through the inhibition of pyruvate dehydrogenase (PDH). In 
addition, HIF1α interacts with PKM2 and promotes its gene transcription [18], further 
implying an instructive role for HIF1α downstream signaling in the Warburg-like 
restructuring of glucose metabolism. 
The derivation of induced pluripotent stem cells (iPSCs), allowing somatic cells to 
acquire embryonic stem cells (ESCs)-like features [19], is also associated with a profound re-
configuration of anabolic demands. Indeed, induced pluripotent stem cells (iPSCs) show high 
proliferation rate and distinct cell cycle features compared to parental somatic cells [20]. This 
suggests that a corresponding reprogramming of energy metabolism may also be in place. 
Accordingly, we previously discovered that somatic mitochondria and cellular bioenergetics 
are extensively remodeled upon cellular reprogramming as the cells adopt a glycolytic 
metabolism [21]. Following these initial observations, several groups further confirmed that a 
Warburg-like metabolic reconfiguration takes place in both mouse and human iPSCs [22-26]. 
Indeed, the process of “metabolic reprogramming” is now being recognized as an emerging 
important step of the induction of pluripotency [27-30]. 
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The metabolic switch of cell fate reprogramming does not appear to be due to 
dysfunctional mitochondria, which are in fact capable of respiring and consume oxygen, as 
demonstrated by bioenergetic profiling studies [25, 26, 31]. However, like cancer cells, 
proliferating pluripotent stem cells (PSCs) may opt for glycolysis as they necessitate building 
biomass and at the same time maintaining redox homeostasis. In accordance, PSCs exhibit up-
regulation of genes involved in glucose uptake and the initial steps of glycolysis, increased 
expression of PDK1 [25, 31], suggesting the re-routing of metabolism outside of the 
mitochondria, and elevated levels of glucose-6-phosphate (G6P) [31], indicative of enhanced 
flux through the pentose phosphate pathway. Moreover, ROS levels are also reduced in PSCs 
and so is the amount of oxidative damage [21, 32]. Finally, exposure to hypoxic environment 
favorably supports self-renewal and pluripotency [33-35], enhances iPSC generation [36], and 
maintain hESCs in a more developmentally immature state [37]. 
Here, we sought to investigate the mechanisms underlying the metabolic 
reprogramming occurring upon cell fate transition and specifically dissect the contribution of 
the HIF1α pathway. We found that a small molecule mimicking HIF1α activation enhances 
reprogramming, while the ablation of HIF1α results in a dramatic loss of colony formation. 
By performing transcriptional and bioenergetic profiling during early reprogramming, we 
discovered that the transduction of the four factors is sufficient to up-regulate PDK1 and 
thereby initiating a glycolytic shift. The exposure to hypoxia or to HIF1α activation further 
stimulates the expression PDK3 and PKM2, resulting in increased early switch to glycolysis 
and more efficient iPSC generation. The additional up-regulation of PDK3 and PKM2 might 
be critical in enhancing reprogramming, since we observed that their expression is elevated in 
undifferentiated PSCs and is coupled to reduced PK activity, all traits associated with a 
glycolytic state. Taken together, early induction of HIF1α-associated glycolytic modulators 
may be instrumental in the establishment of pluripotency and may possibly represent an 
enabling regulatory step during cell fate conversion. 
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Materials and Methods 
Cell lines and culture conditions 
Neonatal foreskin fibroblasts (FFs) HFF1 and BJ were purchased from ATCC (# SCRC-1041 
and #CRL-2522, respectively) and dermal fibroblasts (DFs) NFH2 were previously derived 
from an 84 year-old woman [38]. All fibroblasts were cultured using DMEM supplemented 
with 10% bovine serum, nonessential amino acids, L-glutamine, penicillin/streptomycin, and 
sodium pyruvate (all from Invitrogen, CA). All iPSC lines were previously generated using 
the four Yamanaka  factors retroviral cocktail: HFF1-derived iPSCs (lines iPS2 and iPS4) 
[21], BJ-derived iPSCs (lines iB4 and iB5) [31], NFH2-derived iPSCs (lines OiPS3, OiPS6, 
OiPS8, and OiPS16) [38]. hESC lines H1 and H9 (WiCell) and iPSCs were cultured in hESCs 
media containing KO-DMEM supplemented with 20% knockout serum replacement, 
nonessential amino acids, L-glutamine, penicillin/streptomycin, sodium pyruvate, 0.1mM β-
mercaptoethanol (all from Invitrogen, Carlsbad, CA), and 8 ng/ml bFGF (Prepotech, Rocky 
Hill, NJ). Pluripotent stem cells were harvested in feeder-free conditions using DMEM-F12 
media supplemented N2/B27. All cultures were normally kept in a humidified atmosphere of 
5% CO2 at 37°C under atmospheric oxygen condition (20%).  
 
HIF1α activation 
To generate hypoxic conditions, the oxygen concentration was set to 1% and the cells were 
maintained under hypoxia for 24h. A small molecule activator of HIF1α was employed, ethyl 
3,4-dihydroxybenzoate (EDHB) (Sigma, #E24859), at a concentration of 100µM of, as 
previously shown [39]. To test the effect of HIF1α activation on the early reprogramming-
initiating events, FFs were transduced twice with the four factor retroviral cocktail (OSKM), 
as previously described [40], alone or in combination with 100µM EDHB treatment. The cells 
were then harvested after 24h from the first transduction (4F 24h and 4F EDHB 24h), after 
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48h from the first transduction (that means 24h after the second transduction) (4F 48h and 4F 
EDHB 48h), and after 72h from the first transduction (4F 72h and 4F EDHB 72h). In 
addition, FFs were treated only with 100µM EDHB for 24h (EDHB 24h), 48h (EDHB 48h), 
and 72h (EDHB 72h). 
 
HIF1α knockdown 
To stably knockdown HIF1α, BJ fibroblasts were transduced with lentiviruses containing 
shRNA sequences against human HIF1α (BJ-HIF1-KD) and scrambled control 
oligonucleotides (BJ-SCR-KD) (TIB MOLBIOL, Berlin, Germany) [41]. Oligonucleotides 
were inserted into the lentiviral bicistronic vector pPR1, which allows for co-expression of 
GFP [42]. Recombinant lentiviruses were produced in 293T cells using the calcium-phosphate 
method. Human BJ fibroblasts stably expressing shRNAs were generated by double 
transduction with lentiviruses at a multiplicity of infection (MOI) of 10 for 24h. Transduction 
efficiency of target cells was determined by flow cytometry analysis of GFP using a 
FACSCalibur (Becton Dickinson, Heidelberg, Germany).  
 
Cellular reprogramming 
To test the consequences of HIF1α manipulation on the overall efficiency of iPSC generation, 
BJ fibroblasts, SCR-KD BJ fibroblasts, HIF1-KD BJ fibroblasts, and BJ fibroblasts treated 
with EDHB were reprogrammed to pluripotency using retroviral vectors expressing the four 
Yamanaka factors (4F: OCT4, SOX2, KLF4, and c-MYC), following our previously 
published protocol [21]. To test the effect of HIF1α knockdown on viral-free iPSC derivation, 
BJ fibroblasts, SCR-KD BJ fibroblasts, and HIF1-KD BJ fibroblasts were transfected using 
three non-integrative episomal plasmids containing a total of seven factors (4F plus NANOG, 
LIN28, and SVLT), as previously described [43]. Briefly, 8×10
5
 fibroblasts (BJ, SCR-KD, 
and HIF1-KD) were nucleofected using the Amaxa Cell Line Nucleofector Kit (Lonza, Basel, 
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Switzerland). After nucleofection, fibroblasts were immediately mixed with 500µl DMEM 
medium before seeding into six-well plates. The following day, the cells were cultured using 
ESC medium supplemented with a small molecule cocktail composed by CHIR99021, A-83-
01, PD0325901, and Y-27632 (all from Stemgent) [43]. Four weeks after either retroviral or 
plasmid reprogramming, the cells were fixed and stained for NANOG expression using the 
ABC method (see below). The reprogramming efficiency was defined as the number of 
NANOG positive colonies relative the total starting number of fibroblasts. 
 
Global gene expression analysis 
Biotin-labeled cRNA samples were produced as previously decribed [21] and hybridized onto 
Illumina human-8 BeadChips version 3 (Illumina, San Diego, CA, United States). The 
following samples were used: BJ, BJ-HIF1-KD, BJ-SCR-KD, 4F 24h, 4F 48h, 4F 72h 
(hybridized in duplicate), EDHB 24h, EDHB 48h, EDHB 72h, 4F EDHB 24h, 4F EDHB 48h, 
4F EDHB 72h (hybridized in single). In addition, previously generated array data were 
incorporated in the analysis, including: amniotic fluid cells (AFCs), foreskin fibroblasts (FFs) 
(HFF1 and BJ), dermal fibroblast (DFs) (NFH2), hESC lines (H1 and H9), FFiPSC lines 
(iPS2, iPS4, iB4, and iB5), DFiPSC lines (OiPS3, OiPS6, OiPS8, and OiPS16) (all hybridized 
in duplicate) and AFiPSC (lines 4, 5, 6, 10, hybridized in single, and line 41, hybridized in 
duplicate) [21, 31, 38, 44]. Microarray analysis, PCA plot, and the general heatmap were 
performed using the R/Bioconductor package. Genes were considered significantly expressed 
with detection p values ≤ 0.01. Differential expression analysis was performed using the 
Illumina custom method, using differential p values ≤ 0.01, fold change ratio > 1.5. The 
heatmap for energy metabolism was generated using Microarray Software Suite TM4 
(TMEV.bat) with an input list adapted from SA Biosciences PCR arrays (Human Glucose 
Metabolism PCR Array, www.sabiosciences.com). Pathway analysis was determined by 
mapping onto KEGG pathways using Database for Annotation, Visualization and Integrated 
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Discovery (DAVID) (http://david.abcc.ncifcrf.gov). Microarray results have been deposited in 
the GEO database (accession number GSE37709).  
 
Quantitative real-time PCR (qPCR) 
Real-Time PCR was performed in 384 or 96 Well Optical Reaction Plates (Applied 
Biosystems, Foster City, CA, United States) using SYBR®Green PCR Master Mix (Applied 
Biosystems). Reactions were carried out on the ABI PRISM 7900HT Sequence Detection 
System (Applied Biosystems). Duplicate or triplicate amplifications were carried out for each 
target gene with at least three wells serving as negative controls. Quantification was 
performed using the comparative Ct method (ABI instruction manual), normalized over 
ACTB, and presented as a log2 values with respect to the biological controls. The list of all 
primers used in this study is presented in Supp. Table 4. 
 
Immunostaining and western blotting  
Avidin-Biotin Complex (ABC) method was used to stain NANOG-positive hESC-like 
colonies, as described elsewhere [45]. Briefly, after primary incubation with NANOG 
antibody (1:100, Abcam #ab62734), biotinylated universal secondary antibody was applied 
following the manufacturer's instruction (Vector Laboratories, ABC universal kit #PK-6200). 
The ABC reagent was then added to bind HRP to the primary/secondary complex. HRP 
enzyme activity was then visualized using the chromogen substrate diaminobenzidine 
tetrachloride (DAB, Sigma # D5637). Senescence-associated β-galactosidase staining was 
performed according to the manufacturer's protocol (Cell Signaling, Danvers, MA, USA, 
www.cellsignal.com). Cells stained for NANOG or β-galactosidase were photographed using 
a digital camera (Canon). 
For western blot analysis, nuclear protein extracts were prepared as described in details before 
[46], then resolved by electrophoresis on an 8% sodium dodecyl sulfate-polyacrylamide gel, 
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and transferred to a nitrocellulose membrane (Amersham Biosciences, Freiburg, Germany). 
Blots were probed with antibodies against HIF1α (AB1536; R&D Systems, Minneapolis, MN, 
USA), HIF2α (ab199, Abcam, Cambridge, UK), and YY1 (sc-281; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Secondary antibodies were conjugated to Horseradish 
Peroxidase (Dianova, Hamburg, Germany) and peroxidase activity was visualized using the 
Western Lightning Chemiluminescence Reagent Plus (Perkin Elmer Life Sciences, Boston, 
Massachusetts, USA). 
 
Absolute quantification (AQUA) of PKM1 and PKM2 
The mass spectrometry-based AQUA approach was used to determine the absolute 
quantification of PKM1 and PKM2 isoforms, as previously described [8]. Briefly, protein 
samples from yeasts carrying p414TEF-PKM1 or p413TEF-PKM2, somatic cells, and 
pluripotent stem cells were separated on a 10% SDS-PAGE gels and the mass region between 
50-70 kDa were excised. The gel pieces were then subjected to an “in-gel” tryptic digest. The 
AQUA peptide mixture (20 µL), containing all three AQUA peptides, was spiked to the 
samples as soon as the tryptic digest was completed. For quantitation of the tryptic peptides of 
interest, their corresponding AQUA analogue were spiked in the samples after the tryptic 
digest. Analysis was performed on a nanoLC (Eksigent, Ultra 2D) coupled online to a hybrid 
triple quadrupole/ion trap mass spectrometer (AB/SCIEX, QTRAP 5500). The identity of the 
quantified peptides was confirmed by collecting of MS/MS spectra on the QTRAP operating 
in iontrap mode. In order to confirm specificity of the selected tryptic peptides, yeasts 
expressing either only PKM1 or PKM2 were employed. The quantitative values obtained for 
PKM1 and PKM2 were set in ratio with PKM1+2 and all samples were corrected accordingly. 
 
Pyruvate kinase (PK) activity 
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PK was assessed using the Pyruvate Kinase Activity Assay Kit (MAK072, Sigma), according 
to the manufacture`s instruction. Briefly, cells were rapidly homogenized and the rate of PK 
activity was measured by assessing the fluorescence intensity every 5 minutes until the value 
of the most active sample was higher than the one of the highest standard. The results were 
then reported to the total number of cells calculated according to the BCA protein assay kit 
(23225, Pierce, Thermo Scientific). Both PK and protein measurements were obtained with a 
Tecan reader (InfiniteM200). 
  
Bioenergetic profiling 
Assessment of cellular energy metabolism was performed using Seahorse XF24 extra-cellular 
flux analyzer (Seahorse Bioscience, www.seahorsebio.com), as previously described [31]. 
The instrument allows the simultaneous quantification of mitochondrial respiration (oxygen 
consumption rate, OCR) and glycolysis to lactic acid (extracellular acidification rate, ECAR). 
Four mitochondrial inhibitors (all from Sigma) were used in succession. After three basal 
measurements, 1µM oligomycin, a complex V blocker, was added to inhibit OXPHOS. After 
time point 6, the uncoupling agent FCCP was injected into the wells leading to the collapse of 
the mitochondrial membrane potential and to the consumption of oxygen in the absence of 
ATP production. The same FCCP concentration (1µM) was added again after time point 9 to 
monitor the continuous mitochondrial uncoupling. Finally, 1µM rotenone (complex I blocker) 
and 1µM antimycin A (complex III blocker) were simultaneously injected to completely 
inhibit mitochondrial respiration, thus enabling the calculations of both mitochondrial and 
non-mitochondrial respiratory fractions. 40,000 fibroblasts were plated into each well of the 
XF-24 well plates approximately 18h before the analysis. Assays were initiated by removing 
the growth medium and replacing it with unbuffered media, prepared as previously described 
[31].  
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Statistical analysis 
Data are expressed as mean and standard error of the mean (SEM), unless stated otherwise. 
Data were analyzed using GraphPad-Prism software (Prism 4.0, GraphPad Software, Inc.) and 
Windows XP Excel (Microsoft). 
 
Results 
HIF1α activation stimulates glycolysis and enhances the efficiency of reprogramming  
We previously discovered that the protein expression level of PDK1 is elevated in 
human PSCs compared to somatic cells or to PSC-differentiated cells [31]. These findings 
have been independently demonstrated [25] and further supported by the observation that 
small molecule-based PDK1 induction can significantly improve cellular reprogramming 
[22]. Since PDK1 is a known downstream target of HIF1α [15, 16], we first sought to 
determine the level of HIFα protein expression in undifferentiated PSCs. In agreement with 
previous data obtained on hESCs [34], we verified that HIF1α and HIF2α are not 
constitutively activated in human PSCs (Figure 1A). The pattern of nuclear accumulation 
following hypoxic stimulation was a bit different for HIF1α and HIF2α, as it was comparable 
in both fibroblasts and PSCs for HIF1α and instead only present in PSCs for HIF2α, 
suggesting that HIF2α could play a more important role in undifferentiated stem cells, as 
previously described [47].  
We then investigated whether HIF1α activation may influence the induction of 
pluripotency. We observed that the daily addition of 100µM of the PHD inhibitor ethyl-3,4-
dihydroxybenzoate (EDHB) to BJ foreskin fibroblasts could lead to significant increase in the 
efficiency of reprogramming (from 0.001% in BJ cells to 0.005% in BJ cells treated with 
EDHB). This was assayed based on the number of hESC-like colonies expressing the 
pluripotency-regulating protein NANOG four weeks after retroviral transduction of the four 
Yamanaka factors (4F) (Figure 1B, Student’s t test, 4F versus 4F EDHB, p=0.0063). These 
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findings are in agreement with a previous report showing that a different PHD inhibitor, N-
oxaloylglycine, and another HIF1α inducer, Quercetin, could lead to increased efficiency of 
cellular reprogramming in human fibroblast cells [22]. Moreover, HIF1α over-expression has 
been found to improve the induction of iPSC-like colonies in the A549 cancer cell line [48]. 
Since we previously demonstrated that reprogramming to pluripotency is associated 
with a shift to glycolysis [21], we tested whether the HIF1α activator that facilitated 
reprogramming was capable of enhancing glycolysis. Indeed, short-term treatment with 
EDHB was sufficient to decrease the rate of cellular OXPHOS (Figure 1C) and increase 
glycolytic metabolism (Figure 1D). Several parameters related to mitochondrial respiration 
were strongly lowered by the treatment, including the basal respiration, the ATP turnover, the 
maximal respiration rate, and the spare respiratory capacity (Supp. Fig. 1). Overall EDHB 
significantly reduced the ratio between oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) (Figure 1E, Student’s t test, EDHB treated versus untreated, 
p<0.005), indicative of a switch to glycolysis. Hence, mimicking HIF1α stimulation in 
somatic cells can amplify the Warburg-like metabolic shift thereby improving iPSC 
generation.  
 
HIF1α depletion down-regulates the glycolytic pathway and hampers iPSC generation 
In order to establish whether the activation of the HIF1α pathway during 
reprogramming is critical for the generation of iPSCs rather than simply supportive, we stably 
knocked-down HIF1α in BJ fibroblasts (HIF1-KD) using a lentivirus-based RNA interference 
approach. A scrambled knockdown (SCR-KD) was included as control. Immunoblot analysis 
confirmed that HIF1-KD fibroblasts were incapable of accumulating HIF1α protein within the 
nucleus under hypoxic exposure (Figure 2A). Both HIF1-KD BJ and SCR-KD BJ exhibited 
normal fibroblast-like growth features and did not show signs of early senescence, as shown 
by β-galactosidase staining (Supp. Fig.2A).  
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Strikingly, NANOG-positive colonies failed to appear in HIF1-KD cells 
reprogrammed with the 4F retroviral transduction (Figure 2B), while SCR-KD cells retained 
the ability to give rise to NANOG-positive hESC-like colonies with an efficiency 
approximately similar to that of wild type BJ fibroblasts (around 0.001%) (Figure 2B). The 
addition of EDHB was not sufficient to overcome the reprogramming block in HIF1-KD cells 
(data not shown). In addition, we assessed the effect of HIF1α depletion using an alternative 
non-integrative episomal plasmid reprogramming approach [43]. Consistent with the 
retroviral data, wild-type BJ and SCR-KD BJ fibroblasts transfected with the episomal 
plasmids could generate NANOG-positive colonies with a similar efficiency (around 
0.0008%) after four weeks of reprogramming (Figure 2B). However, HIF1-KD BJ fibroblasts 
failed to derive hESC-like colonies (Figure 2B). These results imply that cells depleted of 
HIF1α may be incapable of achieving a pluripotent state regardless of the reprogramming 
method, pointing towards an instrumental role of HIF1α in the induction of pluripotency.  
We then sought to gain insights into the possible mechanisms responsible for the 
inability of HIF1-KD cells to undergo efficient reprogramming and performed global 
transcriptomics. Reassuringly, the results confirmed HIF1A as the most down-regulated gene 
in HIF1-KD BJ compared to SCR-KD BJ (Supp. Table 1). Interestingly, pathway analysis 
revealed that among the most significantly down-regulated pathways in HIF1-KD compared 
to SCR-KD (fold change > 1.5) there were the mTOR signaling pathway, which is known to 
be associated with HIF1α and the regulation of energy metabolism [4], and the pathways 
related to glycolysis and gluconeogenesis (Figure 2C). We then assessed the bioenergetic 
profiling of fibroblasts and found that the lack of HIF1α did not alter their basal glucose 
metabolism, as indicated by the maintenance of OCR/ECAR ratio (Figure 2D).  Indeed, the 
rate of OXPHOS (Supp. Fig. 2B) and glycolysis (Supp. Fig. 2B) appeared similar in HIF1-
KD fibroblasts, SCR-KD, and wild-type BJ fibroblasts. Overall, the data suggest that HIF1α 
ablation may not be sufficient to alter the basal metabolism of fibroblasts but it might hinder 
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reprogramming through the down-regulation of target genes that have to be activated in order 
to enable the establishment of pluripotency. Since genes associated with glycolysis and 
gluconeogenesis have been previously found to be up-regulated in undifferentiated PSCs 
compared to fibroblasts [25, 31], it may be conceivable that cells that are not capable of 
correctly activating a glycolytic program may also be refractory to efficient iPSC conversion. 
 
Up-regulation of HIF1α-associated metabolic regulators during initiation of 
reprogramming  
To follow up the hypothesis that knockdown of HIF1α may alter the transcriptional re-
configuration of energy metabolism and that this may be crucial for reprogramming, we 
sought to focus on regulated gene expression occurring within the initiation phase of iPSC 
derivation. Indeed, we previously observed that the Gene Ontology (GO) biological process 
of “response to hypoxia” was significantly regulated during early reprogramming [40]. We 
thus analyzed the transcriptome of foreskin fibroblasts (FFs) at 24h, 48h, and 72h after i) 
treatment with 100µM EDHB (EDHB 24h, 28h, 72h), ii) transduction with the four 
reprogramming factors (4F 24h, 48h, 72h), and iii) both (4F EDHB 24h, 48h, 72h). These data 
were compared to the transcriptome of fully reprogrammed iPSCs derived from FFs [21, 31], 
from adult dermal fibroblasts (DFs) [38], and from amniotic fluid cells (AFCs) [44], and of 
hESCs.  
Principal component analysis (PCA) revealed that at these early time points neither 
HIF1α manipulation nor 4F retroviral transduction was sufficient to extensively alter the 
global transcriptional signature of somatic cells, which clustered together and apart from all 
PSCs (Figure 3A). The expression level of the most significantly highly up- or down-
regulated genes (fold change > 20) in PSCs compared to somatic cells remained unaffected in 
somatic fibroblasts exposed to 4F transduction and/or HIF1α activation (Figure 3B). In 
particular, among these top-regulated genes, none appeared regulated in EDHB-treated 
Page 16 of 72
 17 
fibroblasts (Supp. Table 2) and only a few genes related to the viral-mediated introduction of 
transcription factors (such as OCT4, the OCT4 pseudogene-1, and the cancer-associated H19) 
were up-regulated in early 4F-transduced fibroblasts (Supp. Table 2). 
We next focused on genes associated with HIF1α, energy metabolism, and mTOR 
signaling pathways (Supp. Table 3). The mRNA expression level of HIF1A and HIF2A genes 
was not altered upon early reprogramming or EDHB treatment (Supp. Table 3), as also 
confirmed by qPCR analyses (Supp. Fig. 3A). Accordingly, no changes in HIF1A or HIF2A 
gene expression could be observed in PSCs compared to somatic cells, both under normoxic 
and hypoxic exposure (Supp. Fig. 3B). This is in agreement with previous findings showing 
the lack of HIF1A transcriptional activation under hypoxia in hESCs [34]. Interestingly, 
however, the expression of some of the genes associated with energy metabolism underwent 
modifications during early reprogramming (Supp. Table 3, Supp. Fig. 4). Among the 
metabolism-related genes exhibiting early up-regulation in 4F-transduced cells or EDHB-
treated cells, we identified three HIF1α target factors known to regulate a reconfiguration of 
energy flux: PKM2, PDK1, and PDK3 (Supp. Fig. 4).  
PKM2, PDK1, and PDK3 gene expression in fibroblasts showed an increase following 
EDHB treatment, as confirmed by qPCR analysis (Figure 4A). This is in agreement with 
previous data linking HIF1α activation with PDK1-3 induction [15-17] and with PKM2 gene 
transcription [18]. Importantly, the sole introduction of the four factors into fibroblasts 
resulted in the early up-regulation of PDK1 (Figure 4A). On the other hand, PKM2 and PDK3 
were not up-regulated following 4F transduction (Figure 4A), indicating that the conventional 
Yamanaka protocol may not be sufficient to induce the early expression of these two factors 
which instead require the additional activation of the HIF1α pathway.  
Finally, we confirmed that elevated expression of these three glycolytic regulators 
could occur in human fibroblasts following both EDHB treatment (Figure 4B) and hypoxic 
exposure (Figure 4C). Importantly, PKM2, PDK1, and PDK3 were not up-regulated in HIF1-
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KD fibroblasts treated with EDHB (Figure 4B, one-way ANOVA, p<0.005) or cultured under 
hypoxia (Figure 4C, one-way ANOVA, p<0.005). No alteration of the basal expression of 
genes associated with the pathways of HIF1α, energy metabolism, and mTOR could be 
detected in HIF1-KD compared to SCR-KD (with the exception of the down-regulation of 
HIF1a) (Supp. Table 3). Hence, although fibroblasts bearing HIF1α knockdown showed a 
normal fibroblast-like basal metabolism (Figure 2D) and normal fibroblast-like metabolic-
related transcriptional signature (Supp. Table 3), they appeared incapable of up-regulating the 
expression of key glycolytic inducers. This implicates the Warburg-like transcriptional 
modulation of energy metabolism as a potential enabling step for initiating cellular 
reprogramming. 
 
Elevated expression of the HIF1α-related glycolytic regulators PKM2, PDK1, and PDK3 
in pluripotent stem cells  
We next investigated the association of the three HIF1α-related metabolic regulators 
with pluripotency. The expression level of PDK1, PDK3, and PKM2 was measured in 
FFiPSCs, DFiPSCs and hESCs, under both normoxia and 24h 1% hypoxia, and compared it 
to that in FFs (for FFiPSCs), DFs (for DFiPSCs), and all somatic fibroblasts (for hESCs) 
grown under normoxic conditions. In agreement with previous protein expression data [25, 
31], the transcriptional level of PDK1 appeared up-regulated in all PSCs (Figure 5A). 
However, PDK1 induction was statistically significant in iPSCs only under hypoxic 
conditions (Figure 5A, Student’s t test, hypoxic iPSCs versus normoxic fibroblasts, p<0.05), 
while both normoxic and hypoxic hESCs exhibited significant PDK1 up-regulation (Figure 
5A, Student’s t test, normoxic/hypoxic hESCs versus normoxic fibroblasts p<0.005). PDK3 
was significantly up-regulated in both iPSCs (Figure 5B, Student’s t test, normoxic/hypoxic 
iPSCs versus normoxic fibroblasts p<0.05) and hESCs (Figure 5B, Student’s t test, 
normoxic/hypoxic hESCs versus normoxic fibroblasts p<0.005) under normoxia and hypoxia, 
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although it was more elevated in iPSCs under hypoxic growth (Figure 5B, Student’s t test, 
hypoxic iPSCs versus normoxic fibroblasts p<0.005). Hence, the exposure to hypoxia led to 
increased up-regulation of PDK1 and PDK 3 in all iPSCs but not in hESCs, which showed 
elevated expression of the two genes already under normoxic growth (Figure 5A and 5B). 
This differential response to hypoxic stimuli between somatic-derived and embryonic-derived 
PSCs may be explained by recent evidence demonstrating that they may not be equivalent in 
terms of their pluripotency [49-51]. Alternatively, it may be simply due to the known 
heterogeneity displayed by different PSC lines [52]. In any case, further studies are warranted 
to dissect this differential response to hypoxic stimuli between iPSCs and hESCs.  
 In order to dissect the role of PKM2 in PSCs, we first sought to employ mass 
spectrometry-based targeted proteomic analysis. This approach allows the quantification of 
the absolute amount of the two alternatively-spliced isoforms encoded by the PKM2 gene, 
PKM1 and PKM2, and it was previously carried out in healthy and tumor-associated tissues 
[8]. Remarkably, in comparison to fibroblasts, both iPSCs and hESCs exhibited reduced 
PKM1 (Figure 5C, Student’s t test, PSCs versus FFs p<0.05) coupled with significantly 
elevated amounts of PKM2 (Figure 5D, Student’s t test, PSCs versus FFs p<0.005). Overall, 
the PKM2/PKM1 ratio appeared significantly increased in PSCs under both normoxic and 
hypoxic conditions (Figure 5E, Student’s t test, normoxic/hypoxic PSCs versus 
normoxic/hypoxic FFs p<0.01). The PKM2 isoform is known to display reduced enzymatic 
activity [12]. Thus, we next measured the PK functionality in fibroblasts and PSCs and 
identified a diminished PK activity in all PSCs (Figure 5F, Student’s t test, PSCs versus wild-
type BJ, p<0.005). This implies that the elevated expression of PKM2 in PSCs may be 
functionally relevant and could contribute to the maintenance of the glycolytic phenotype of 
PSCs.  
Taken together, undifferentiated iPSCs and hESCs express high levels of three HIF1α 
downstream targets, whose function mediates a Warburg-like effect by increasing the energy 
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flux in the upstream glycolytic branches and PPP, which may eventually lead to biomass 
stimulation and redox maintenance [6, 7]. Furthermore, since reprogramming efficiency is 
increased upon EDHB treatment (Figure 1B) or hypoxic stimulation [36], it is tempting to 
speculate that the elevated expression of PKM2 and PDK3 detected in fibroblasts exposed to 
EDHB or hypoxia (Figure 4B and 4C) may possibly play a role in improving the conversion 
to iPSCs by additional metabolic modulation towards a glycolytic state.  
 
Metabolic remodeling during initiation of reprogramming  
Finally, we asked whether the transcriptional activation of metabolic regulators during 
reprogramming initiation was sufficient to induce a metabolic reconfiguration. Bioenergetic 
profiling of fibroblasts following 4F transduction indicated that mitochondrial respiration 
increased over the first three days of reprogramming (Figure 6A). However, the elevation of 
glycolysis appeared more pronounced (Figure 6B). The additional treatment with EDHB 
resulted in enhanced glycolytic conversion, with drastic OCR reduction (Figure 6C) and 
higher ECAR values (Figure 6D). Overall, 4F transduction led to progressive decrease in the 
OCR/ECAR ratio, indicative of initial conversion to glycolytic metabolism (Figure 6E, 
Student’s t test, 4F-transduced BJ versus wild-type BJ, p<0.05). In accordance, the amount of 
extracellular lactate in 4F-tranduced fibroblasts showed a similar gradual increase during the 
first days of reprogramming (Figure 6F, Student’s t test, 4F-transduced BJ versus wild-type 
BJ, p<0.05). Nonetheless, this metabolic remodeling does not appear to be completed at these 
early stages, as shown by the much higher lactate secretion occurring in fully reprogrammed 
iPSCs and hESCs (Figure 6F, Student’s t test, PSCs versus BJ, p<0.005). The additional 
exposure to a drug mimicking HIF1α activation may thus improve the efficiency of iPSC 
generation through the early enhancement of glycolytic activation, as shown by a dramatic 
OCR/ECAR decrease (Figure 6E, Student’s t test, 4F-EDHB treated BJ versus BJ, p<0.005).   
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On the basis of data herein presented, we suggest that the introduction of the four 
Yamanaka factors in human fibroblasts may be sufficient to up-regulate the HIF1α target 
PDK1, which can in turn initiate a glycolytic program. On the other hand, the inclusion of 
hypoxia or EDHB treatment may stimulate the expression of additional HIF1α-related 
metabolic regulators PDK3 and PKM2, enhancing the glycolyitc shift at the very early stages 
of reprogramming and eventually leading to improved iPSC derivation. Finally, 
reprogramming may be inhibited in cells that are incapable of activating HIF1α and up-
regulating these three metabolic regulators, further underlying the importance of HIF1α-
associated metabolic restructuring in the induction of pluripotency in somatic cells (Figure 7). 
 
Discussion 
We and others have previously demonstrated that cell fate reprogramming is 
associated with a transition from respiratory to glycolytic metabolism [21-26]. Tumor cells 
are believed to undergo similar metabolic transformation events in order to sustain the cost of 
anabolic reactions caused by their high proliferative rate and resistance to stress signals [4]. 
Thus, metabolic adaptation appears as a crucial mechanism for proliferating cells, which 
require to build biomass and the same time preserve the redox balance [6]. Here, we sought to 
uncover possible mechanistic pathways underlying the metabolic reprogramming of iPSCs 
and demonstrated that HIF1α, a master regulator of glucose metabolism [13, 14], plays a 
critical role during the induction of pluripotency by modulating the early establishment of a 
glycolytic program. 
Hypoxia and HIF1α have been previously implicated in the maintenance of 
pluripotency. Indeed, hypoxic conditions have been found to lead to improved stemness and 
reprogramming [33, 36]. HIF1α activation could induce hESC-like signature in cancer cell 
lines [48] and drive mouse ESCs to acquire glycolytic features upon transition towards an 
epiblast stem cell (EpiSC)-like state [53]. Moreover, stabilization of hypoxia and HIF1α 
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inhibits the metabolic shift to OXPHOS that is required for efficient differentiation of human 
mesenchymal stem cells [54]. Hypoxic exposure may also increase the protein expression 
UCP2 [55], a regulator of energy metabolism in undifferentiated PSCs [26]. Finally, hypoxia 
might lead to OCT4 reactivation to promote the de-differentiation of PSC-derived progenies 
[56]. Our results provide additional support for all these findings and demonstrate that cells 
incapable of activating a HIF1α response might also be refractory to reprogramming, thus 
underlying the critical importance of this pathway for the induction and maintenance of 
pluripotency.  
Our data suggest that a glycolytic shift may be instrumental for reprogramming as it 
may be set into motion during the reprogramming initiation stage through the early up-
regulation of the HIF1α target PDK1. Indeed, PSCs exhibit elevated PDK1 protein expression 
[25, 31]. Moreover, small molecule-based activation of PDK1 can improve iPSC derivation 
[22], while PDK1 inhibitors lead to reduced hESC-like colony formation [23]. Hence, PDK1 
may possibly represent an early marker of reprogramming involved in the Warburg-like 
metabolic restructuring associated with the conversion to pluripotency.  
The findings also provide additional support to previous data showing that during 
reprogramming, glycolysis-associated genes may be up-regulated prior to genes involved in 
self-renewal and pluripotency [23]. Furthermore, transcriptional changes in the processes 
related to cellular metabolism have been detected during the first initial wave of 
reprogramming, which has been suggested to be under the control of KLF4 and c-MYC [57]. 
It is thus tempting to speculate that KLF4 and c-MYC may be driving the transcriptional and 
bioenergetic modulation observed during the initiation of cellular reprogramming. Indeed, the 
oncogene c-MYC can co-operate with HIF1α  to induce a transcriptional program leading to 
stimulated glycolytic activity [58, 59], although a glycolytic shift has been observed even in 
iPSCs derived in the absence of c-MYC [23]. KLF4 may be capable of activating glycolytic 
metabolism in cancer cells [60] and KLF5, which can substitute KLF4 in the reprogramming 
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cocktail [61], can regulate energy metabolism and up-regulates uncoupling protein 2 (UCP2) 
[62], a protein recently linked to  the glycolytic state of PSCs [26]. Nonetheless, it may as 
well be that the key stemness factor OCT4 could regulate downstream targets implicated in 
OXPHOS and glycolysis [28, 63]. In fact, OCT4 expression intermingles with HIF signaling 
pathways [47] and may positively interact with PKM2 [64]. Further studies are warranted to 
clearly dissect the specific roles of the Yamanaka factors in the remodeling of energy 
metabolism of reprogrammed cells. 
Finally, since reconfiguration of glucose metabolism could have significant 
advantages in preventing redox imbalance [5, 65], it is conceivable that iPSC generation may 
require such metabolic reprogramming in order to safeguard the genome integrity. Nuclear 
and mitochondrial genetic defects have been reported in human iPSCs [31, 66, 67]. Perhaps, 
the suppression of metabolic resetting may function as a reprogramming roadblock by 
inducing an uncontrolled rise of genomic damage which may be incompatible with 
continuous cell growth. In accordance, pro-oxidant reactions can promote PSC differentiation 
[68].  
It is important to note that our analyses were performed on whole cultures and may 
thus not necessarily mirror the situation occurring in the small percentage of cells actually 
undergoing reprogramming. Reassuringly, a recent work employing single-cell analysis 
showed that reprogramming is initiated in the majority of virally transduced fibroblasts, 
although only completed in a smaller cellular subpopulation [69]. Since we mainly focused on 
early reprogramming initiation, it is then possible that our data may reflect real 
reprogramming-related cellular conditions. Nevertheless, given the known heterogeneity of 
single PSC lines [49, 52], it would be of interest to repeat our relatively small-scale 
investigation (which included two hESC lines and thirteen human iPSC lines derived from 
three different cell sources, i.e. foreskin fibroblasts, dermal fibroblasts, and amniotic fluid 
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cells) using larger datasets of several human and murine PSCs to clearly demonstrate the role 
of HIF1α and glycolytic regulation in cell fate conversion. 
Overall, our results indicate that HIF1α-mediated reconfiguration of glucose 
metabolism may represent an early enabling step of cellular reprogramming, a barrier that has 
to be overcome in order to make somatic cells capable of sustaining their newly acquired 
proliferative and biosynthetic needs. We anticipate that the study of metabolism in stem cells 
may unveil critical mechanisms governing the induction of pluripotency, eventually 
elucidating the pathways responsible for allowing this remarkable example of cellular 
plasticity.  
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Figure legends 
Figure 1. Mimicking HIF1α activation facilitates iPSC reprogramming. (A) HIF1α and 
HIF2α nuclear accumulation in foreskin fibroblasts (FFs), hESCs, and FFs-derived iPSCs 
(FFiPSCs) under normoxic conditions (N) and following 24h hypoxic incubation with 1% 
oxygen (H). The transcription factor YY1 was used for normalization of nuclear extracts. (B) 
BJ fibroblasts were transduced with the four factor cocktail (4F) alone or in combination with 
daily treatment with 100µM EDHB (4F EDHB). All cells were plated under reprogramming 
conditions, fixed four weeks later, and immunostained against the pluripotency-associated 
protein NANOG, according to the Avidin-Biotin Complex (ABC) protocol. The experiments 
were repeated three times. Bar graphs represent the mean and standard deviation of the 
average number of NANOG-positive hESC-like colonies detected. **p=0.0063, two-tailed 
Unpaired Student’s t test, 4F EDHB versus 4F (C) Oxygen consumption rate (OCR), 
indicative of OXPHOS activity, was assessed using the Seahorse cellular flux analysis. Wild 
type FFs (BJ cells) (black line) were compared to FFs treated with EDHB for 24h (yellow 
line), 48h (orange line), and 72h (red line). (D) Extracellular acidification rate (ECAR), 
indicative of glycolytic activity, was measured at the same time as OCR in the same samples. 
(E) OCR/ECAR ratio was calculated in order to generate a clear estimate of the overall 
metabolic state of the cells. ***p<0.005, two-tailed Unpaired Student’s t test: EDHB 24h 
versus BJ (p=0.0043), EDHB 48h versus BJ (p=0.0025), and EDHB 72h versus BJ 
(p=0.0032). 
 
Figure 2. HIF1α knockdown inhibits reprogramming. (A) Immunoblot analysis confirmed 
that HIF1-KD BJ fibroblasts were incapable of accumulating HIF1α protein in the nucleus 
upon hypoxic stimulation while SCR-KD BJ fibroblasts retained this ability. (B) Wild-type 
BJ fibroblasts, SCR-KD BJ fibroblasts, and HIF1-KD BJ fibroblasts were reprogrammed to 
pluripotency using either a classical retroviral approach with the four Yamanaka factors (4F: 
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OCT4, SOX2, KLF4, and c-MYC) or with episomal plasmids (expressing the four factors 
plus NANOG, LIN28, and SV40L). After four weeks of culturing under hESC conditions, 
wild type BJ and SCR-KD BJ cells developed hESC-like colonies in a comparable fashion, as 
shown by the similar number of colonies that resulted positive for the pluripotency-associated 
marker NANOG (monitored with the Avidin-Biotin Complex method). However, NANOG-
positive hESC-like colonies  were not generated in HIF1-KD BJ cells, regardless of the 
reprogramming method employed. (C) List of the most significantly down-regulated 
pathways (fold change > 1.5) in HIF1-KD BJ compared to SCR-KD BJ. (D) The ratio of 
OCR/ECAR, indicating the metabolic cell state, was calculated in fibroblasts maintained 
under basal conditions using the seahorse bioanalyzer. 
 
Figure 3. Transcriptional modulation during reprogramming initiation. (A) Principal 
component analysis (PCA) showing the clustering of the transcriptomes of the following 
somatic cells: FFs, DFs, amniotic fluid cells (AFCs), FFs knocked-down for HIF1α 
(HIF1.KD) and knocked-down for a scrambled transcript (SCR-KD), FFs transduced with the 
four factors only for 24, 48, and 72h (4F 24h, 4F 48h, 4F 72h) or in combination with daily 
100 µM EDHB (4F EDHB 24h, 4F EDHB 48h, 4F EDHB 72h), and FFs only treated with 
EDHB (EDHB 24h, EDHB 48h, EDHB 72h), and the following pluripotent stem cells: 
hESCs, FFiPSCs, DFiPSCs, and AFCs-derived iPSCs (AFiPSCs). (B) Heatmap depicting the 
genes most highly down and up-regulated (fold change > 20) in somatic-derived and 
embryonic-derived pluripotent stem cells compared to wild type untreated somatic cells. 
Different iPSCs were compared to their respective somatic cells, while hESCs were compared 
to the average of all wild-type somatic cells. The samples include wild-type untreated somatic 
cells (grey bar), FFs harvested 24h, 48h, and 72h after 4F transduction (green bar), FFs treated 
with EDHB for the same time points (yellow bar), FFs exposed to both 4F and EDHB 
treatment (purple bar), iPSCs (black bar), and hESCs (red bar). Values indicate row-
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normalized log2 average expression values; down-regulated genes are indicated in green, up-
regulated genes in red.  
 
Figure 4. Up-regulation of HIF1α-related metabolic regulators during early 
reprogramming. (A) qPCR analysis of HIF1α targets known to play a role in regulating 
glycolytic metabolism (PKM2, PDK1, and PDK3) during the first three days of 
reprogramming initiation. Relative mRNA level to ACTB is presented in comparison to wild-
type untreated FFs. Green line: FFs transduced with the four factors; yellow line: FFs treated 
with EDHB; purple line: FFs transduced with the 4F and treated with EDHB at the same time. 
(B) Expression of PKM2, PDK1, and PDK3 after 24h EDHB treatment in wild type FFs (BJ 
and HFF1), SCR-KD fibroblasts, and HIF1-KD fibroblasts. ***p<0.005, One-way ANOVA 
single factor: PKM2 (p=5 E-07), PDK1 (p=9 E-06), and PDK3 (p=1 E-07). (C) 
Transcriptional level of the three glycolytic regulators after 24h exposure to 1% hypoxia. 
***p<0.005, One-way ANOVA single factor: PKM2 (p=4 E-05), PDK1 (p=9 E-08), and 
PDK3 (p=1 E-07).   
 
Figure 5. PKM2, PDK1, and PDK3 are highly expressed in PSCs. (A) Relative PDK1 
mRNA expression in: FFiPSCs (iPS2, iPS4, iB4, and iB5) under normoxia and hypoxia in 
relation to normoxic FFs (HFF1 and BJ); DFiPSCs (OiPS6, OiPS8, and OiPS16) under 
normoxia and hypoxia in relation to normoxic DFs (NFH2); and hESCs (H1 and H9) under 
normoxia and hypoxia in relation to all fibroblasts (HFF1, BJ, and NFH2) grown under 
normoxic conditions. **p=0.0098, two-tailed Unpaired Student’s t test, hypoxic FFiPSCs 
versus normoxic FFs. *p=0.043, two-tailed Unpaired Student’s t test, hypoxic DFiPSCs 
versus normoxic DFs. ***p<0.005, two-tailed Unpaired Student’s t test: normoxic hESCs 
versus all normoxic fibroblasts (p=0.0005), hypoxic hESCs versus all normoxic fibroblasts 
(p=0.0011). (B) Relative expression of PDK3 in PSCs under normoxia and hypoxia compared 
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to normoxic somatic fibroblasts. *p=0.023, two-tailed Unpaired Student’s t test, normoxic 
FFiPSCs versus normoxic FFs. **p=0.0061, two-tailed Unpaired Student’s t test, normoxic 
DFiPSCs versus normoxic DFs. ***p<0.005, two-tailed Unpaired Student’s t test: normoxic 
hESCs versus all normoxic fibroblasts (p=0.0007), hypoxic FFiPSCs versus normoxic FFs 
(p=0.0009), hypoxic DFiPSCs versus normoxic DFs (p=0.0021), hypoxic hESCs versus all 
normoxic fibroblasts (p=0.0002) (C) Absolute protein quantification of PKM1 in FFs, 
FFiPSCs, and hESCs. *p<0.05, two-tailed Unpaired Student’s t test, FFiPSCs versus FFs and 
hESCs versus FFs. (D) Absolute protein quantification of PKM2 in FFs (HFF1 and BJ), 
FFiPSCs (iPS2, iPS4, iB4, and iB5), and hESCs (H1 and H9). ***p<0.005, two-tailed 
Unpaired Student’s t test, FFiPSCs versus FFs and hESCs versus FFs. (E) PKM2/PKM1 ratio 
in FFs, FFiPSCs, and hESCs grown under normoxic and hypoxic conditions. **p<0.01, two-
tailed Unpaired Student’s t test, normoxic hESCs versus normoxic FFs. ***p<0.005, two-
tailed Unpaired Student’s t test, normoxic FFiPSCs versus normoxic FFs, hypoxic FFiPSCs 
versus hypoxic FFs, and hypoxic hESCs versus hypoxic FFs. (F) Rate of PK activity, 
normalized over the total protein amount, was measured in wild type FFs (BJ and HFF1), 
SCR-KD and HIF1-KD fibroblasts, FFiPSCs (iB4, and iB5), and hESCs (H1 and H9). 
***p<0.005, two-tailed Unpaired Student’s t test, iB4 versus BJ, iB5 versus BJ, H1 versus BJ, 
and H9 versus BJ. 
 
Figure 6. Metabolic shift during early reprogramming. (A) OCR profile of wild-type FFs 
(BJ) and FFs after 24h, 48h, and 72h from 4F transduction. (B) ECAR profile of FFs at the 
basal level and after 4F introduction. (C) OCR profile in BJ fibroblasts treated with the HIF1α 
mimicker EDHB in addition to the 4F transduction. (D) ECAR profile in FFs and 4F-EDHB 
FFs. (E) OCR/ECAR ratio gradually decreases during reprogramming initiation while it is 
drastically reduced upon the additional introduction of EDHB to the reprogramming cocktail. 
*p=0.0370, two-tailed Unpaired Student’s t test, 4F 48h versus BJ. **p=0.0062, two-tailed 
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Unpaired Student’s t test, 4F 72h versus BJ. ***p<0.005, two-tailed Unpaired Student’s t test: 
4F EDHB 24h versus BJ (p=0.0045), 4F EDHB 48h versus BJ (p=0.0001), and EDHB 72h 
versus BJ (p=0.0002). (F) Production of extracellular lactate in FFs (BJ, SCR-KD, HIF1-KD), 
FFs transduced with the 4F, hESCs (H1 and H9), and BJ-FFiPSCs (iB4 and iB5). The values 
are reported to the amount of lactate generated in control wild-type BJ fibroblasts. *p<0.05, 
two, two-tailed Unpaired Student’s t test: 4F 24h versus BJ (p=0.035), 4F 48h versus BJ 
(p=0.021). **p<0.01, two-tailed Unpaired Student’s t test, 4F 72h versus BJ (p=0.008). 
***p<0.005, two-tailed Unpaired Student’s t test: hESCs versus BJ (p=0.0035), BJ FFiPSCs 
versus BJ (p=0.0041).  
 
Figure 7. HIF1α-associated metabolic reconfiguration during reprogramming initiation.  
Cartoon depicting the potential mechanisms through which the introduction of the 4F or the 
modulation of HIF1α pathway might regulate glycolytic metabolism during the early stages of 
somatic cell reprogramming. The introduction of the 4F in somatic fibroblasts up-regulates 
the HIF1α target PDK1, which re-routes the energy flux outside the mitochondria, thereby 
enhancing the glycolytic metabolism. HIF1α activation up-regulates additional HIF1α targets 
PKM2 and PDK3, further increasing the glycolytic shift and eventually resulting in improved 
conversion to pluripotency.  
 
Supp. Figure 1. (A) Basal respiration in BJ fibroblasts and in BJ fibroblasts treated for three 
days with 100µM EDHB was calculated by subtracting the OCR values following rotenone 
and antimycin A treatment from the basal OCR values. (B) ATP turnover was estimated by 
subtracting OCR measurements after oligomycin introduction from the basal OCR 
measurements. (C) Maximal respiration rate was calculated by subtracting the OCR values 
after rotenone and antimycin a exposure from the OCR values after FCCP exposure. (D) 
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Spare respiratory capacity was estimated by subtracting the basal OCR measurements from 
OCR measurements following FCCP injection.  
 
Supp. Figure 2. (A) Neonatal foreskin fibroblasts BJ were transduced with lentiviruses 
containing shRNA sequences against human HIF1α (BJ-HIF1-KD) and scrambled control 
oligonucleotides (BJ-SCR-KD). The transduced cells maintained fibroblast-like growth 
features and did not display signs of senescence, as shown by lack of β-galactosidase staining. 
(B) OCR profile of BJ, SCR-KD, and HIF1-KD fibroblasts. (C) ECAR profile of BJ, SCR-
KD, and HIF1-KD fibroblasts. 
 
Supp. Figure 3. (A) HIF1A and HIF2A expression level in FFs following 4F transduction 
and/or EDHB treatment. (B) HIF1A and HIF2A expression level in normoxic and hypoxic 
FFiPSCs, DFiPSCs, and hESCs in relation to normoxic FFs, DFs, and FFs + DFs, 
respectively.  
 
Supp. Figure 4. Heatmap and clustering of genes involved in energy metabolism (list taken 
from the Human Glucose Metabolism PCR Array). Values represent the ratio over wild-type 
untreated FFs; down-regulated genes are indicated in green, up-regulated genes in red. PDK1, 
PDK3, and PKM2 are shown with blue arrows. 
 
Supplementary Table 1. List of the 30 most significantly down-regulated genes and 30 most 
significantly up-regulated genes in HIF1-KD cells compared to SCR-KD cells. Reported are 
the average (AVG) signals of the top genes in the two samples, the differential p values 
calculated between HIF1-KD and SCR-KD (light blue, p<0.05; dark blue, p<0.01), the ratios 
calculated as the AVG signal of HIF1-KD over the AVG signal of SCR-KD, and the log2 
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ratio values (fold change down-regulation >1.5 is depicted in green, fold change up-regulation 
>1.5 in red). 
 
Supplementary Table 2. List of the genes most highly up- and down-regulated (fold change 
> 20) in PSCs compared to somatic cells. Reported are the average intensity values of all the 
samples utilized for global gene expression analysis. Genes up-regulated in comparison to 
wild-type fibroblasts are highlighted in red, down-regulated genes in green. 
 
Supplementary Table 3. List of genes associated with HIF1α, energy metabolism, and 
mTOR/autophagy. Reported are the LOG2 ratio values of PSCs over the respective somatic 
fibroblasts (FFs for FFiPSCs, DFs for DFiPSCs, AFCs for AFiPSCs, FFs plus DFs and AFCs 
for hESCs), FFs transduced with the 4F or treated with EDHB over untreated wild-type FFs, 
and HIF1-KD BJ fibroblasts over SCR-KD BJ fibroblasts. Up-regulated genes are highlighted 
in red. 
 
Supplementary Table 4. List of primers used for quantitative real-time PCR.  
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Figure 1. Mimicking HIF1α activation facilitates iPSC reprogramming. (A) HIF1α and HIF2α nuclear 
accumulation in foreskin fibroblasts (FFs), hESCs, and FFs-derived iPSCs (FFiPSCs) under normoxic 
conditions (N) and following 24h hypoxic incubation with 1% oxygen (H). The transcription factor YY1 was 
used for normalization of nuclear extracts. (B) BJ fibroblasts were transduced with the four factor cocktail 
(4F) alone or in combination with daily treatment with 100µM EDHB (4F EDHB). All cells were plated under 
reprogramming conditions, fixed four weeks later, and immunostained against the pluripotency-associated 
protein NANOG, according to the Avidin-Biotin Complex (ABC) protocol. The experiments were repeated 
three times. Bar graphs represent the mean and standard deviation of the average number of NANOG-
positive hESC-like colonies detected. **p=0.0063, two-tailed Unpaired Student’s t test, 4F EDHB versus 4F 
(C) Oxygen consumption rate (OCR), indicative of OXPHOS activity, was assessed using the Seahorse 
cellular flux analysis. Wild type FFs (BJ cells) (black line) were compared to FFs treated with EDHB for 24h 
(yellow line), 48h (orange line), and 72h (red line). (D) Extracellular acidification rate (ECAR), indicative of 
glycolytic activity, was measured at the same time as OCR in the same samples. (E) OCR/ECAR ratio was 
calculated in order to generate a clear estimate of the overall metabolic state of the cells. ***p<0.005, two-
tailed Unpaired Student’s t test: EDHB 24h versus BJ (p=0.0043), EDHB 48h versus BJ (p=0.0025), and 
EDHB 72h versus BJ (p=0.0032).  
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Figure 2. HIF1α knockdown inhibits reprogramming. (A) Immunoblot analysis confirmed that HIF1-KD BJ 
fibroblasts were incapable of accumulating HIF1α protein in the nucleus upon hypoxic stimulation while SCR-
KD BJ fibroblasts retained this ability. (B) Wild-type BJ fibroblasts, SCR-KD BJ fibroblasts, and HIF1-KD BJ 
fibroblasts were reprogrammed to pluripotency using either a classical retroviral approach with the four 
Yamanaka factors (4F: OCT4, SOX2, KLF4, and c-MYC) or with episomal plasmids (expressing the four 
factors plus NANOG, LIN28, and SV40L). After four weeks of culturing under hESC conditions, wild type BJ 
and SCR-KD BJ cells developed hESC-like colonies in a comparable fashion, as shown by the similar number 
of colonies that resulted positive for the pluripotency-associated marker NANOG (monitored with the Avidin-
Biotin Complex method). However, NANOG-positive hESC-like colonies  were not generated in HIF1-KD BJ 
cells, regardless of the reprogramming method employed. (C) List of the most significantly down-regulated 
pathways (fold change > 1.5) in HIF1-KD BJ compared to SCR-KD BJ. (D) The ratio of OCR/ECAR, indicating 
the metabolic cell state, was calculated in fibroblasts maintained under basal conditions using the seahorse 
bioanalyzer.  
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Figure 3. Transcriptional modulation during reprogramming initiation. (A) Principal component analysis 
(PCA) showing the clustering of the transcriptomes of the following somatic cells: FFs, DFs, amniotic fluid 
cells (AFCs), FFs knocked-down for HIF1α (HIF1.KD) and knocked-down for a scrambled transcript (SCR-
KD), FFs transduced with the four factors only for 24, 48, and 72h (4F 24h, 4F 48h, 4F 72h) or in 
combination with daily 100 µM EDHB (4F EDHB 24h, 4F EDHB 48h, 4F EDHB 72h), and FFs only treated with 
EDHB (EDHB 24h, EDHB 48h, EDHB 72h), and the following pluripotent stem cells: hESCs, FFiPSCs, 
DFiPSCs, and AFCs-derived iPSCs (AFiPSCs). (B) Heatmap depicting the genes most highly down and up-
regulated (fold change > 20) in somatic-derived and embryonic-derived pluripotent stem cells compared to 
wild type untreated somatic cells. Different iPSCs were compared to their respective somatic cells, while 
hESCs were compared to the average of all wild-type somatic cells. The samples include wild-type untreated 
somatic cells (grey bar), FFs harvested 24h, 48h, and 72h after 4F transduction (green bar), FFs treated 
with EDHB for the same time points (yellow bar), FFs exposed to both 4F and EDHB treatment (purple bar), 
iPSCs (black bar), and hESCs (red bar). Values indicate row-normalized log2 average expression values; 
down-regulated genes are indicated in green, up-regulated genes in red.  
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Figure 4. Up-regulation of HIF1α-related metabolic regulators during early reprogramming. (A) qPCR 
analysis of HIF1α targets known to play a role in regulating glycolytic metabolism (PKM2, PDK1, and PDK3) 
during the first three days of reprogramming initiation. Relative mRNA level to ACTB is presented in 
comparison to wild-type untreated FFs. Green line: FFs transduced with the four factors; yellow line: FFs 
treated with EDHB; purple line: FFs transduced with the 4F and treated with EDHB at the same time. (B) 
Expression of PKM2, PDK1, and PDK3 after 24h EDHB treatment in wild type FFs (BJ and HFF1), SCR-KD 
fibroblasts, and HIF1-KD fibroblasts. ***p<0.005, One-way ANOVA single factor: PKM2 (p=5 E-07), PDK1 
(p=9 E-06), and PDK3 (p=1 E-07). (C) Transcriptional level of the three glycolytic regulators after 24h 
exposure to 1% hypoxia. ***p<0.005, One-way ANOVA single factor: PKM2 (p=4 E-05), PDK1 (p=9 E-08), 
and PDK3 (p=1 E-07).  
77x59mm (600 x 600 DPI)  
 
 
Page 40 of 72
  
 
 
Figure 5. PKM2, PDK1, and PDK3 are highly expressed in PSCs. (A) Relative PDK1 mRNA expression in: 
FFiPSCs (iPS2, iPS4, iB4, and iB5) under normoxia and hypoxia in relation to normoxic FFs (HFF1 and BJ); 
DFiPSCs (OiPS6, OiPS8, and OiPS16) under normoxia and hypoxia in relation to normoxic DFs (NFH2); and 
hESCs (H1 and H9) under normoxia and hypoxia in relation to all fibroblasts (HFF1, BJ, and NFH2) grown 
under normoxic conditions. **p=0.0098, two-tailed Unpaired Student’s t test, hypoxic FFiPSCs versus 
normoxic FFs. *p=0.043, two-tailed Unpaired Student’s t test, hypoxic DFiPSCs versus normoxic DFs. 
***p<0.005, two-tailed Unpaired Student’s t test: normoxic hESCs versus all normoxic fibroblasts 
(p=0.0005), hypoxic hESCs versus all normoxic fibroblasts (p=0.0011). (B) Relative expression of PDK3 in 
PSCs under normoxia and hypoxia compared to normoxic somatic fibroblasts. *p=0.023, two-tailed 
Unpaired Student’s t test, normoxic FFiPSCs versus normoxic FFs. **p=0.0061, two-tailed Unpaired 
Student’s t test, normoxic DFiPSCs versus normoxic DFs. ***p<0.005, two-tailed Unpaired Student’s t test: 
normoxic hESCs versus all normoxic fibroblasts (p=0.0007), hypoxic FFiPSCs versus normoxic FFs 
(p=0.0009), hypoxic DFiPSCs versus normoxic DFs (p=0.0021), hypoxic hESCs versus all normoxic 
fibroblasts (p=0.0002) (C) Absolute protein quantification of PKM1 in FFs, FFiPSCs, and hESCs. *p<0.05, 
two-tailed Unpaired Student’s t test, FFiPSCs versus FFs and hESCs versus FFs. (D) Absolute protein 
quantification of PKM2 in FFs (HFF1 and BJ), FFiPSCs (iPS2, iPS4, iB4, and iB5), and hESCs (H1 and H9). 
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***p<0.005, two-tailed Unpaired Student’s t test, FFiPSCs versus FFs and hESCs versus FFs. (E) 
PKM2/PKM1 ratio in FFs, FFiPSCs, and hESCs grown under normoxic and hypoxic conditions. **p<0.01, two-
tailed Unpaired Student’s t test, normoxic hESCs versus normoxic FFs. ***p<0.005, two-tailed Unpaired 
Student’s t test, normoxic FFiPSCs versus normoxic FFs, hypoxic FFiPSCs versus hypoxic FFs, and hypoxic 
hESCs versus hypoxic FFs. (F) Rate of PK activity, normalized over the total protein amount, was measured 
in wild type FFs (BJ and HFF1), SCR-KD and HIF1-KD fibroblasts, FFiPSCs (iB4, and iB5), and hESCs (H1 and 
H9). ***p<0.005, two-tailed Unpaired Student’s t test, iB4 versus BJ, iB5 versus BJ, H1 versus BJ, and H9 
versus BJ.  
80x90mm (600 x 600 DPI)  
 
 
Page 42 of 72
  
 
 
Figure 6. Metabolic shift during early reprogramming. (A) OCR profile of wild-type FFs (BJ) and FFs after 
24h, 48h, and 72h from 4F transduction. (B) ECAR profile of FFs at the basal level and after 4F introduction. 
(C) OCR profile in BJ fibroblasts treated with the HIF1α mimicker EDHB in addition to the 4F transduction. 
(D) ECAR profile in FFs and 4F-EDHB FFs. (E) OCR/ECAR ratio gradually decreases during reprogramming 
initiation while it is drastically reduced upon the additional introduction of EDHB to the reprogramming 
cocktail. *p=0.0370, two-tailed Unpaired Student’s t test, 4F 48h versus BJ. **p=0.0062, two-tailed 
Unpaired Student’s t test, 4F 72h versus BJ. ***p<0.005, two-tailed Unpaired Student’s t test: 4F EDHB 
24h versus BJ (p=0.0045), 4F EDHB 48h versus BJ (p=0.0001), and EDHB 72h versus BJ (p=0.0002). (F) 
Production of extracellular lactate in FFs (BJ, SCR-KD, HIF1-KD), FFs transduced with the 4F, hESCs (H1 and 
H9), and BJ-FFiPSCs (iB4 and iB5). The values are reported to the amount of lactate generated in control 
wild-type BJ fibroblasts. *p<0.05, two, two-tailed Unpaired Student’s t test: 4F 24h versus BJ (p=0.035), 4F 
48h versus BJ (p=0.021). **p<0.01, two-tailed Unpaired Student’s t test, 4F 72h versus BJ (p=0.008). 
***p<0.005, two-tailed Unpaired Student’s t test: hESCs versus BJ (p=0.0035), BJ FFiPSCs versus BJ 
(p=0.0041).  
66x74mm (600 x 600 DPI)  
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Figure 7. HIF1α-associated metabolic reconfiguration during reprogramming initiation.  
Cartoon depicting the potential mechanisms through which the introduction of the 4F or the modulation of 
HIF1α pathway might regulate glycolytic metabolism during the early stages of somatic cell reprogramming. 
The introduction of the 4F in somatic fibroblasts up-regulates the HIF1α target PDK1, which re-routes the 
energy flux outside the mitochondria, thereby enhancing the glycolytic metabolism. HIF1α activation up-
regulates additional HIF1α targets PKM2 and PDK3, further increasing the glycolytic shift and eventually 
resulting in improved conversion to pluripotency.  
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Supp. Figure 1. (A) Basal respiration in BJ fibroblasts and in BJ fibroblasts treated for three days with 500µM 
EDHB was calculated by subtracting the OCR values following rotenone and antimycin A treatment from the 
basal OCR values. (B) ATP turnover was estimated by subtracting OCR measurements after oligomycin 
introduction from the basal OCR measurements. (C) Maximal respiration rate was calculated by subtracting 
the OCR values after rotenone and antimycin a exposure from the OCR values after FCCP exposure. (D) 
Spare respiratory capacity was estimated by subtracting the basal OCR measurements from OCR 
measurements following FCCP injection.  
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Supp. Figure 2. (A) Neonatal foreskin fibroblasts BJ were transduced with lentiviruses containing shRNA 
sequences against human HIF1α (BJ-HIF1-KD) and scrambled control oligonucleotides (BJ-SCR-KD). The 
transduced cells maintained fibroblast-like growth features and did not display signs of senescence, as 
shown by lack of β-galactosidase staining. (B) OCR profile of BJ, SCR-KD, and HIF1-KD fibroblasts. (C) ECAR 
profile of BJ, SCR-KD, and HIF1-KD fibroblasts.  
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Supp. Figure 3. (A) HIF1A and HIF2A expression level in FFs following 4F transduction and/or EDHB 
treatment. (B) HIF1A and HIF2A expression level in normoxic and hypoxic FFiPSCs, DFiPSCs, and hESCs in 
relation to normoxic FFs, DFs, and FFs + DFs, respectively.  
45x37mm (600 x 600 DPI)  
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Supp. Figure 4. Heatmap and clustering of genes involved in energy metabolism (list taken from the Human 
Glucose Metabolism PCR Array). Values represent the ratio over wild-type untreated FFs; down-regulated 
genes are indicated in green, up-regulated genes in red. PDK1, PDK3, and PKM2 are shown with blue 
arrows.  
383x649mm (300 x 300 DPI)  
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TargetID SCR-KD.AVG_Signal HIF1-KD.AVG_Signal HIF-KD.Diff Pval
1 HIF1A 840.37 148.78 7.82E-13
2 PPFIA4 84.86 15.87 1.48E-02
3 CX3CR1 165.06 36.21 8.46E-05
4 ZBTB7A 119.43 28.36 1.04E-02
5 A2M 363.17 88.63 3.16E-08
6 TNFRSF10D 178.66 43.82 1.36E-04
7 PTHR1 216.62 54.33 6.49E-06
8 AMOT 103.90 26.69 1.22E-02
9 HSPB3 1847.28 519.46 8.05E-11
10 CCND2 414.99 117.53 3.03E-08
11 MMP11 2446.98 711.70 8.47E-09
12 TPP2 179.72 55.40 8.52E-03
13 COMP 81.98 25.84 4.69E-02
14 C1ORF190 85.02 27.07 4.28E-02
15 COL8A2 572.80 182.80 6.20E-07
16 RARB 198.53 63.56 2.41E-03
17 LRRC32 357.85 118.34 8.01E-06
18 SLC24A3 169.56 56.95 2.20E-03
19 SPINT2 684.61 230.24 1.60E-06
20 RNF212 87.82 30.08 4.76E-02
21 MARK1 354.36 124.31 1.47E-06
22 UCN2 90.20 32.54 4.31E-02
23 ERMP1 227.06 86.23 1.75E-03
24 CST6 99.11 37.73 3.67E-02
25 SUSD2 200.96 76.64 9.41E-04
26 CCDC109B 704.32 269.38 3.33E-05
27 EXTL1 165.32 63.56 3.42E-03
28 FAIM3 160.53 62.84 4.42E-03
29 PPP1R14A 710.25 279.08 1.04E-06
30 DRD1IP 141.03 55.42 1.29E-02
1 RSAD2 5.00 728.98 3.68E-38
2 IL8 5.00 277.53 1.03E-11
3 IFI27 211.69 7817.48 3.68E-38
4 CMPK2 5.00 183.86 5.60E-08
5 SST 5.00 174.17 1.52E-06
6 IFI44L 133.28 4235.28 3.68E-38
7 OAS1 28.77 853.60 2.05E-23
8 SLC39A8 5.00 124.54 6.84E-05
9 HERC5 116.68 2846.25 3.68E-38
10 LRRC17 5.00 106.51 1.92E-04
11 CYP1B1 97.30 1777.36 3.68E-38
12 TMEFF2 6.58 119.41 1.17E-04
13 SLC16A6 6.57 106.72 9.43E-04
14 OAS2 217.19 2963.19 3.88E-22
15 LGALS9 5.00 60.47 2.24E-02
16 GNA14 11.17 135.00 3.86E-05
17 BST2 69.97 815.40 4.44E-16
18 MX2 339.01 3924.26 8.88E-16
19 HERC6 464.37 4422.53 3.68E-38
20 ZNF804A 10.26 95.11 2.59E-03
21 DTX3L 23.64 205.78 2.83E-07
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22 ESM1 38.48 329.90 6.30E-11
23 EPSTI1 847.96 7178.81 3.68E-38
24 RTP4 32.05 269.82 2.35E-09
25 OASL 29.40 240.89 1.80E-06
26 MX1 4012.46 32269.70 3.68E-38
27 C6ORF192 36.24 273.41 1.66E-09
28 HCP5 109.21 819.36 2.22E-16
29 CLDN1 152.92 1132.21 1.36E-12
30 DDX58 186.47 1368.32 3.68E-38
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HIF1-KD/SCR-KD ratio LOG2 ratio
0.18 -2.50
0.19 -2.42
0.22 -2.19
0.24 -2.07
0.24 -2.03
0.25 -2.03
0.25 -2.00
0.26 -1.96
0.28 -1.83
0.28 -1.82
0.29 -1.78
0.31 -1.70
0.32 -1.67
0.32 -1.65
0.32 -1.65
0.32 -1.64
0.33 -1.60
0.34 -1.57
0.34 -1.57
0.34 -1.55
0.35 -1.51
0.36 -1.47
0.38 -1.40
0.38 -1.39
0.38 -1.39
0.38 -1.39
0.38 -1.38
0.39 -1.35
0.39 -1.35
0.39 -1.35
145.80 7.19
55.51 5.79
36.93 5.21
36.77 5.20
34.83 5.12
31.78 4.99
29.67 4.89
24.91 4.64
24.39 4.61
21.30 4.41
18.27 4.19
18.15 4.18
16.24 4.02
13.64 3.77
12.09 3.60
12.09 3.60
11.65 3.54
11.58 3.53
9.52 3.25
9.27 3.21
8.70 3.12
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8.57 3.10
8.47 3.08
8.42 3.07
8.19 3.03
8.04 3.01
7.54 2.92
7.50 2.91
7.40 2.89
7.34 2.88
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20fold up FF DF AFCs FFiPSCs DFiPSCs AFiPSCs hESCs
TUBB2B 339.4 107.8 1127.1 13008.9 25569.1 35359.8 55087.2
CCND2 92.1 17.6 709.2 5116.3 8773.9 6650.5 20533.3
RBPMS2 87.3 134.4 123.0 3309.3 9153.0 5955.2 17482.0
APOE 46.7 21.9 158.7 8362.5 17693.0 18141.2 16683.2
CNTNAP2 5.0 14.1 35.7 2766.6 4057.5 3741.5 12686.7
LIN28 5.0 12.9 35.9 2800.2 11011.3 10065.9 11741.5
DPPA4 5.0 15.7 40.2 2141.7 7855.9 5809.9 11455.7
GAL 198.8 24.5 54.0 4259.8 11770.7 3930.1 10287.3
ZIC2 5.0 13.5 40.8 1573.3 2957.0 6490.3 8292.6
MT1G 75.2 32.9 204.3 473.0 3191.4 6615.1 8089.2
CDH1 5.0 20.7 65.7 2584.3 7252.0 5521.5 7060.2
CRABP1 5.0 16.8 38.7 779.6 2887.1 2152.7 7057.5
SCNN1A 5.0 20.1 67.8 928.6 3713.6 3037.8 6772.2
POU5F1 5.0 14.4 36.1 1038.8 4999.3 5339.9 6760.6
PROM1 5.0 14.1 232.9 2697.6 5117.8 4855.7 6227.9
RCOR2 49.4 49.4 75.9 897.8 1601.0 2504.6 5943.8
RASL11B 10.6 29.8 42.7 836.1 2591.0 4721.2 5925.3
ZSCAN10 5.0 11.5 33.6 1469.9 5193.4 6049.5 5893.4
MT1H 5.0 18.7 38.1 279.0 1580.0 3327.6 5868.1
HAND1 5.0 15.0 30.8 5766.4 11434.9 785.2 5609.5
KIF1A 5.0 15.6 40.5 3436.8 6858.1 3385.5 5607.8
CST1 5.0 15.4 44.2 3948.1 2832.4 4543.2 5546.9
GLDC 5.0 20.3 59.6 1505.0 3850.2 4251.2 5465.6
NEFM 22.6 21.2 41.7 555.9 388.7 1049.8 4823.6
SOX2 5.0 12.7 30.3 914.6 1447.5 1383.0 4306.9
LIN28B 5.0 16.2 32.5 832.1 2711.1 1343.8 4007.5
APOA2 5.0 15.1 61.7 1861.8 2970.4 758.4 3948.7
ACTA1 5.0 16.9 44.9 7236.6 16719.8 219.3 3615.6
PUNC 5.0 12.5 30.1 1255.6 2628.9 1730.2 3549.4
RAB17 5.0 29.4 122.4 1379.8 1776.2 3431.8 3407.8
CXADR 5.0 16.3 122.5 1169.0 3344.1 1799.0 3223.9
EPHA1 5.0 15.2 70.5 841.7 2261.7 2649.5 3084.0
MYCN 5.0 17.0 42.8 673.6 3605.8 1445.3 3027.2
GDF3 5.0 17.5 40.3 285.6 431.5 1377.3 2886.6
H19 33.0 18.1 47.7 6223.7 13665.5 500.1 2799.9
ZIC3 5.0 17.5 36.0 509.1 2091.4 897.3 2687.6
EOMES 5.0 14.5 29.6 400.8 680.7 774.7 2572.6
PRSS8 5.0 15.1 42.8 723.8 1129.0 679.8 2563.1
KIF5C 5.0 17.9 41.9 780.3 1700.0 1153.8 2545.8
CHD7 10.3 22.0 96.5 921.8 1390.5 919.8 2523.5
KCNK12 5.0 18.0 51.3 688.4 1401.5 1395.9 2512.2
LCP1 5.0 18.2 39.8 1253.7 2994.7 289.6 2467.5
CAMKV 5.0 17.7 36.5 430.5 1503.6 2172.9 2466.6
LEFTY1 5.0 13.0 40.6 815.7 3523.3 560.7 2464.9
WDR72 5.0 14.8 43.3 25.8 670.6 475.6 2459.9
TRIML2 5.0 16.9 49.8 1098.2 2321.4 1379.0 2415.1
CDH3 5.0 16.5 46.2 1047.2 2437.5 2127.0 2413.2
FLJ22662 10.4 31.5 42.5 279.0 908.7 709.8 2400.5
CLDN7 20.5 24.4 52.9 791.3 2491.1 1341.7 2393.0
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NMU 5.0 14.5 34.6 384.2 1791.1 691.0 2387.8
HERC5 10.5 17.3 56.8 339.8 2161.8 806.3 2380.2
NODAL 5.0 23.1 46.2 396.0 1211.6 459.2 2333.0
RPRM 5.0 14.3 33.4 1036.3 3413.1 736.3 2305.3
SALL4 5.0 14.1 45.0 642.5 2792.9 1356.2 2234.3
SOX21 5.0 17.1 53.4 616.2 216.0 2317.5 2226.3
POU5F1P1 5.0 15.9 57.0 1314.8 5942.9 1678.0 2196.1
SBK1 5.0 16.9 44.3 463.9 1268.7 1291.7 2153.2
CGN 5.0 16.4 69.9 934.7 1946.4 1262.1 2064.7
GPM6B 5.0 14.5 35.8 454.0 1277.5 978.4 2044.8
SLC7A3 5.0 16.0 40.0 536.5 1967.4 1326.9 1930.3
D4S234E 5.0 19.5 59.3 528.4 1913.6 1232.8 1921.4
LEFTY2 5.0 15.4 44.6 1300.3 2067.5 283.6 1801.2
VGF 7.5 21.0 77.6 2228.8 5178.8 551.0 1796.6
DLK1 5.0 16.6 46.0 359.8 1405.8 1286.3 1792.6
CRMP1 5.0 17.0 46.7 550.4 1449.6 891.4 1696.1
RIMS3 7.9 16.7 54.7 327.1 588.8 946.9 1686.3
C9ORF135 5.0 16.2 52.1 305.8 1267.4 1154.6 1568.2
LRRN1 5.0 15.9 42.6 456.2 1548.4 1192.4 1508.0
HEY2 5.0 18.7 39.5 414.1 1315.2 602.7 1459.2
SLC16A9 5.0 18.3 47.9 756.3 1028.4 593.2 1440.5
DNMT3B 5.0 24.7 49.0 491.3 3001.0 723.8 1414.2
SOX8 13.1 18.9 51.6 724.7 760.8 1203.9 1412.5
APOA1 5.0 15.1 39.2 2125.8 2440.7 49.6 1385.1
GLIPR1L1 5.0 20.6 45.2 880.1 2779.3 147.5 1373.4
SYT4 5.0 15.8 34.7 141.2 198.1 202.4 1327.7
CPVL 9.2 21.5 52.7 347.1 1516.0 771.2 1326.6
NELL2 5.0 13.0 41.8 489.6 851.1 914.4 1273.5
L1TD1 5.0 20.9 37.6 860.2 2777.5 509.7 1253.1
SST 5.0 14.3 37.1 73.6 354.1 35.9 1245.3
EDNRB 5.5 23.6 43.7 206.5 620.6 985.3 1241.8
FZD3 5.0 17.2 64.1 283.9 275.2 700.6 1203.3
MIXL1 5.0 15.1 25.5 75.9 201.4 171.7 1161.5
OVOL2 5.0 16.5 41.7 237.0 912.2 885.6 1116.4
SILV 5.0 17.8 57.3 184.0 793.7 1483.8 1106.0
TCEAL2 5.0 17.3 43.8 99.4 883.5 649.1 1081.8
COBL 5.0 16.8 42.4 534.6 1391.9 839.5 1047.1
NKD2 5.0 14.5 28.3 278.2 548.1 992.1 1030.9
C1ORF187 5.0 11.6 46.7 453.8 870.8 463.8 942.9
SLC35F1 5.0 13.4 32.8 299.6 277.8 390.8 913.2
RPRML 5.0 20.1 38.3 196.5 375.3 449.0 906.3
FOXA2 5.0 12.6 34.6 158.5 275.8 461.1 877.7
MMP9 5.0 11.5 26.7 455.6 2178.8 464.9 857.9
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4F 24h 4F 48h 4F 72h EDHB 24h EDHB 48h EDHB 72h 4F EDHB 24h 4F EDHB 48h
216.2 718.2 1641.7 161.5 198.7 175.4 202.8 168.7
57.1 83.9 223.4 309.6 203.9 202.8 156.8 172.3
100.9 179.9 170.7 145.8 132.6 114.9 115.4 97.6
109.7 96.0 169.5 110.3 87.3 60.8 65.3 57.6
11.6 5.3 9.1 9.2 12.6 15.1 5.2 6.4
13.2 5.0 5.7 5.0 10.4 11.4 5.0 6.4
21.5 24.2 29.5 11.1 17.3 16.6 7.6 9.3
769.7 1034.0 1468.5 571.3 247.4 215.4 252.5 202.0
21.1 19.9 21.8 14.9 19.0 19.5 14.0 23.6
162.1 167.6 1972.1 264.4 95.8 111.6 168.6 154.2
20.9 22.7 23.2 14.2 17.6 17.9 13.6 14.9
14.6 12.0 11.5 7.7 16.0 13.4 12.2 15.8
18.7 24.9 39.5 13.9 18.1 16.4 11.1 12.6
1306.8 2477.8 2265.9 7.8 12.1 13.4 231.2 446.0
16.4 11.0 20.7 5.0 11.8 10.0 5.3 5.0
73.2 153.0 189.0 25.1 31.8 37.3 28.9 28.5
27.9 29.6 30.3 29.3 37.0 31.9 36.1 20.7
10.1 13.1 11.7 14.2 12.8 11.7 6.2 5.0
23.0 45.2 1233.8 16.9 23.6 22.1 28.6 19.5
120.2 283.7 705.0 6.8 16.1 15.7 15.5 15.2
11.2 5.0 8.0 6.2 12.6 16.7 15.2 7.6
12.0 19.5 28.2 27.6 12.1 16.4 17.2 11.5
21.5 30.5 43.3 19.0 13.2 16.5 14.9 11.5
74.6 83.4 60.9 47.5 31.1 35.6 35.8 58.9
13.1 13.2 10.7 8.1 10.6 7.9 12.1 7.2
10.4 7.9 9.1 21.8 18.9 18.1 37.0 26.7
22.4 18.5 18.3 10.8 21.8 14.5 10.7 14.1
21.3 18.8 22.1 11.1 15.0 16.2 7.4 16.6
15.0 19.0 21.0 6.7 14.9 9.3 12.8 7.4
22.9 21.8 15.4 17.8 20.9 21.2 20.8 16.2
10.1 18.8 69.9 14.4 10.1 14.7 14.0 13.6
20.4 20.8 20.3 17.3 14.9 19.3 13.4 6.3
6.8 5.5 7.8 13.2 22.4 15.0 16.5 11.5
18.2 18.2 36.1 13.2 14.4 13.6 11.3 14.4
1338.0 1263.8 2359.2 39.4 44.3 39.2 476.2 804.3
5.0 10.5 12.2 24.4 13.7 27.1 19.3 13.1
9.1 5.0 5.0 11.8 14.0 22.3 18.8 12.5
9.9 5.0 9.7 16.3 18.6 23.4 11.1 12.1
28.2 16.8 18.4 16.1 22.0 21.0 33.0 38.0
29.7 45.5 58.5 37.9 34.4 34.3 43.0 36.7
23.7 34.2 40.9 18.3 24.7 19.4 13.4 10.8
14.1 13.8 13.8 21.3 19.1 11.2 13.1 8.6
18.1 52.2 46.3 16.8 25.2 24.4 21.4 25.1
7.3 10.8 9.6 10.6 13.3 13.9 10.3 7.7
7.9 13.4 6.6 6.6 8.1 21.8 5.5 5.0
27.5 43.7 121.0 23.1 17.3 19.8 16.0 8.4
18.6 17.3 21.8 17.8 16.1 21.6 15.3 14.4
33.5 39.5 67.2 31.7 28.0 24.2 25.7 27.5
65.1 68.2 112.3 15.5 22.1 18.1 12.8 19.9
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10.3 8.3 15.6 11.2 13.9 17.1 7.6 9.5
884.0 548.7 272.7 34.6 45.5 45.7 2108.4 3806.9
22.0 14.3 14.9 21.1 30.2 29.2 15.8 25.7
20.0 19.8 28.1 8.7 16.9 13.2 15.4 6.4
10.7 13.6 29.5 10.9 12.4 17.7 7.1 14.3
22.6 29.6 62.8 11.1 16.8 15.6 5.5 12.3
1712.9 2822.4 2695.6 8.0 14.5 16.4 364.0 589.2
13.2 12.8 17.0 17.6 12.2 16.9 15.4 21.1
9.3 83.6 116.1 17.3 14.1 17.6 19.5 18.7
17.9 23.1 26.1 18.3 15.0 17.9 7.5 14.4
17.3 12.0 16.1 13.2 15.8 15.3 11.2 14.7
76.1 482.6 778.9 27.6 31.4 28.7 34.5 33.1
17.1 17.7 20.1 15.2 20.3 18.3 7.1 13.2
52.8 61.1 66.9 61.4 40.4 34.2 36.3 43.2
25.9 36.1 77.8 11.2 12.4 11.6 9.0 9.1
19.5 22.9 45.0 17.1 18.0 23.9 17.3 16.7
19.2 15.2 18.3 27.9 21.0 25.0 34.6 30.6
17.2 29.9 164.2 9.8 18.9 23.6 6.6 12.3
12.3 14.5 13.4 16.3 17.8 18.4 16.6 13.2
15.6 11.4 13.1 12.6 16.8 13.3 14.0 15.2
18.7 64.8 67.2 13.5 14.6 18.0 6.9 30.3
22.5 23.6 24.1 24.3 20.1 20.2 30.1 24.1
269.7 316.6 214.6 90.3 101.6 99.1 69.7 73.4
9.5 5.2 6.6 8.5 15.6 19.7 11.6 9.5
21.5 29.8 25.0 18.8 18.3 22.5 17.2 27.2
6.8 5.0 5.2 10.9 17.7 14.2 16.7 13.2
27.0 28.6 25.9 24.8 24.7 25.4 18.1 17.4
12.2 11.6 20.0 8.6 13.8 15.7 10.6 12.3
58.5 191.2 169.3 18.8 22.4 27.7 35.6 33.9
18.8 23.2 45.2 31.7 20.4 19.8 13.0 12.9
18.2 22.0 24.6 23.2 21.4 21.4 20.6 20.5
15.9 8.1 12.2 11.4 17.5 22.3 18.7 10.2
5.0 9.7 12.3 6.1 7.8 11.8 9.7 5.1
14.3 14.6 15.6 10.7 16.9 18.5 14.5 16.9
11.9 9.3 9.3 21.4 26.1 22.6 18.6 23.8
13.4 13.3 17.0 23.7 14.7 21.7 17.5 15.6
14.9 19.2 26.2 17.5 15.2 14.1 20.0 12.9
13.9 15.0 19.1 7.2 14.2 13.6 5.0 5.0
22.9 28.9 16.2 9.6 17.1 15.9 9.1 11.5
18.3 12.1 14.0 11.4 15.7 29.6 15.4 11.1
16.0 60.0 290.8 19.8 21.4 18.1 16.5 17.0
5.0 8.1 10.6 10.9 14.0 12.7 9.8 8.0
7.0 5.0 14.6 12.5 14.0 19.6 5.2 6.5
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4F EDHB 72h HIF KD SCR KD
219.0 343.6 460.6
297.1 71.1 231.0
100.3 162.0 110.3
27.6 43.2 59.6
10.9 5.0 10.3
5.3 6.4 10.8
5.1 9.5 9.1
119.4 31.3 15.9
16.8 10.2 10.8
141.5 42.5 54.0
5.0 29.7 23.2
5.0 6.1 13.3
11.9 12.1 16.7
635.7 7.1 9.9
7.9 5.0 5.4
32.5 22.6 36.8
13.5 21.0 34.6
5.0 6.3 8.4
20.9 16.0 22.1
11.2 5.0 7.5
5.0 15.6 10.0
15.0 9.6 5.0
27.4 10.6 14.3
28.4 35.2 23.3
5.8 5.5 5.0
21.0 9.0 26.0
15.3 11.0 15.9
12.7 10.5 10.1
5.0 10.3 12.9
19.6 10.3 23.2
13.8 7.1 6.9
7.9 13.0 10.9
15.0 19.8 13.2
16.7 8.9 7.2
552.1 25.2 44.6
9.3 22.7 22.9
18.9 17.8 25.7
6.2 10.1 11.3
24.3 30.8 18.9
33.2 28.0 23.4
20.7 6.4 13.2
13.3 6.0 11.4
16.0 18.0 11.2
9.0 5.0 5.0
5.0 9.5 5.2
13.8 19.6 12.2
8.4 5.7 10.2
23.3 53.6 28.1
27.3 25.6 15.6
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5.1 10.0 5.5
4005.4 1606.9 73.2
29.8 17.7 14.7
21.3 6.5 10.9
5.7 6.9 19.3
14.9 11.9 14.0
794.5 5.0 9.1
14.1 23.8 22.3
7.4 12.4 14.6
10.1 6.7 10.7
7.9 12.3 7.6
41.6 22.5 15.3
19.4 14.2 13.4
49.2 37.4 29.1
8.5 8.3 9.4
10.3 15.4 15.8
22.5 24.9 30.2
8.2 9.5 13.0
12.8 11.4 9.7
14.1 24.7 19.4
12.1 13.6 7.7
23.7 18.0 16.2
46.1 65.4 61.3
24.3 9.1 5.0
13.4 22.0 7.7
15.9 6.3 7.5
15.3 13.7 22.4
5.0 5.5 7.2
11.9 15.7 16.9
12.6 102.9 7.5
29.0 24.7 23.0
16.3 11.6 8.0
6.9 5.0 5.0
9.7 10.5 11.5
14.4 18.5 15.1
11.2 10.6 10.0
9.2 10.0 14.0
14.7 9.7 5.0
8.5 6.3 9.1
11.1 8.7 15.1
14.8 13.2 7.1
6.2 6.7 9.9
5.0 5.8 9.8
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20fold down FF DF AFCs FFiPSCs DFiPSCs AFiPSCs hESCs 4F 24h
S100A4 13232.4 10700.6 1570.3 272.9 116.4 599.6 755.9 31915.7
GAS6 3257.3 5060.1 10132.6 755.2 784.2 395.9 668.5 2155.7
THBS1 10621.6 11184.0 24606.4 360.2 1153.6 213.2 659.2 7614.5
CSRP1 2569.5 1766.9 10485.4 1657.9 2792.9 332.7 611.8 2833.8
S100A6 5227.8 3670.5 3668.2 1383.4 1979.2 212.2 588.5 7096.0
CD248 7733.8 5426.3 79.1 314.5 458.0 106.0 574.5 16411.3
ARID5B 2697.2 1775.7 2751.3 271.7 420.5 87.8 519.6 2192.3
IGFBP3 4565.3 6262.1 3919.3 1226.9 2316.5 95.9 477.0 4744.4
WNT5A 2731.9 622.6 162.1 187.0 336.8 46.2 365.3 952.4
RGS4 421.0 1189.6 11568.9 259.6 648.6 43.0 352.9 1357.2
LOX 3986.9 3456.7 6793.6 328.8 365.9 115.4 341.4 9462.5
LMCD1 1699.8 1109.1 340.1 391.1 601.2 127.1 283.3 440.9
SULF1 5348.4 1000.3 2034.6 233.5 281.9 93.7 266.4 6054.0
SELM 1112.4 1130.0 2151.7 147.1 369.2 253.2 244.0 1463.8
LOXL4 2259.0 3321.4 2887.3 329.9 165.7 71.8 235.5 1580.8
CTSK 2363.4 2575.5 82.7 70.5 125.6 123.3 226.4 3420.3
COL8A1 561.5 2139.0 6143.9 212.7 85.9 56.6 203.9 500.9
CYBRD1 3283.3 2920.1 1274.3 63.4 135.8 101.7 200.5 2607.3
DCN 6763.8 3410.5 1069.9 56.4 494.2 21.6 175.3 5640.2
TIMP3 2265.2 718.0 51.8 283.4 395.0 38.9 170.8 3099.3
LAYN 1212.2 1085.2 889.8 97.8 208.2 72.4 168.0 1072.2
FBLN5 1882.6 1367.9 98.8 123.9 236.7 38.3 162.1 1480.3
PPP1R3C 1503.5 959.3 1295.9 50.8 190.0 115.1 160.7 3236.0
MVP 884.6 1037.3 1561.6 123.8 194.7 88.4 159.6 1182.7
VEGFC 888.6 806.7 2155.3 104.9 169.7 42.6 157.5 1666.6
ADAMTS1 1032.1 197.6 610.7 207.3 321.0 51.2 137.1 703.5
GLIPR1 645.3 1216.6 3680.8 194.4 141.3 17.2 135.4 1667.0
NFIX 1640.8 4939.3 2000.1 497.8 284.6 209.5 133.8 1757.2
OXTR 3322.0 2615.2 3039.4 128.4 196.9 40.6 122.8 2058.0
ITGA11 202.2 1110.1 3293.8 33.5 35.5 25.8 121.1 61.7
NNMT 1124.3 692.4 905.0 130.9 177.6 58.9 118.5 556.9
CPA4 668.6 323.6 17227.5 86.0 40.5 15.3 116.6 205.0
COL16A1 1330.1 537.6 374.7 184.4 149.1 58.1 115.0 1205.6
CRYAB 778.6 1988.8 1956.9 89.3 2382.0 44.9 113.9 1240.4
TNFRSF14 704.5 574.6 90.9 110.0 136.1 70.2 105.2 857.0
TMEM119 2630.9 5938.3 32.0 96.6 119.6 33.4 101.6 1331.3
HOXA5 126.5 192.4 4540.1 139.3 331.8 52.5 99.9 182.1
COL12A1 1052.9 1099.0 312.3 79.9 115.0 32.9 93.5 396.3
NTN4 888.5 112.5 911.6 86.7 88.4 48.2 91.1 286.3
LRP10 627.6 748.2 697.6 131.9 289.3 74.1 89.2 640.7
FAP 1556.7 1103.9 1897.9 17.1 15.3 16.0 86.7 1333.5
CERCAM 521.0 776.3 1038.6 100.6 196.7 63.5 84.4 377.6
TMEM173 878.5 1300.9 2365.8 43.3 244.3 18.7 81.6 1424.4
MFAP5 1339.5 1635.4 964.9 383.6 302.6 31.7 79.7 581.9
RCN3 1274.3 650.2 313.0 42.3 61.0 72.5 74.5 2102.8
ANPEP 1809.1 2382.6 951.1 134.2 428.9 26.2 74.0 2569.7
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LY96 877.3 477.8 138.1 50.9 32.2 48.2 71.5 1613.1
FSTL3 298.9 172.1 1767.4 136.6 313.0 59.4 70.6 304.4
ENG 593.6 954.6 741.4 58.4 94.8 59.0 69.9 1070.1
TNFRSF11B 2533.7 785.7 921.8 48.6 28.3 21.9 67.2 1970.6
MEG3 1467.2 1121.8 3933.1 378.3 4668.7 272.5 67.0 2262.5
C1R 1381.3 570.4 56.9 10.5 29.8 78.8 61.2 910.1
CD97 522.6 608.4 786.1 184.0 211.8 195.9 60.4 775.2
ABCC3 594.4 351.8 269.4 100.1 134.3 36.8 58.1 374.7
IFIT2 428.6 112.9 82.2 46.7 160.6 36.3 57.8 3046.5
KIAA1199 6731.8 2543.6 131.5 28.6 151.6 22.2 57.6 2919.8
RECK 1050.0 409.6 174.7 47.1 31.8 13.1 57.1 887.2
NUPR1 775.1 730.0 39.4 63.2 167.6 33.4 56.8 697.8
C1S 895.9 426.0 42.1 21.7 65.2 59.5 56.4 664.4
MYLK 719.8 448.7 319.7 29.3 53.7 35.8 55.5 485.7
MGLL 377.5 301.5 528.9 24.9 39.4 40.5 54.7 622.7
C1QTNF5 395.0 744.5 63.9 42.8 79.8 62.2 50.3 334.8
C10ORF116 825.2 1163.2 109.8 17.3 532.7 39.1 48.3 2660.1
GREM1 638.5 352.6 246.0 54.0 7.6 27.9 46.7 477.9
COX7A1 858.2 1122.1 54.7 32.8 676.2 41.2 44.5 685.9
C15ORF52 955.9 848.5 2540.0 79.8 59.2 37.1 43.0 1576.4
FOXF2 397.0 88.3 52.8 36.9 41.0 33.9 42.6 355.2
TRIM4 494.1 318.8 392.8 137.8 168.2 217.7 38.4 655.5
GPNMB 1137.0 1241.4 50.5 5.0 511.7 37.6 37.1 1252.3
NOV 457.6 163.2 75.7 15.7 26.8 25.4 37.1 619.1
HSPB6 337.8 1148.4 1050.7 17.4 156.2 43.5 36.9 483.8
COPZ2 376.2 252.1 301.0 12.7 21.6 27.8 36.1 711.4
LUM 499.6 85.0 63.5 46.9 39.7 18.6 36.0 202.9
P8 612.3 514.8 48.6 50.2 120.7 19.7 35.5 680.7
UBA7 302.1 243.9 41.6 18.4 52.5 32.4 34.7 603.1
VGLL3 414.3 482.6 218.4 18.2 46.3 21.9 32.6 158.1
PODN 1567.0 940.3 52.8 16.3 16.6 56.4 31.1 1406.1
HSPB3 569.3 1137.3 219.5 7.9 275.1 32.5 30.0 846.6
MXRA8 286.6 819.7 982.2 18.2 90.7 54.3 29.7 467.2
SRGN 357.6 328.5 5394.7 14.7 19.1 27.7 28.4 260.7
WNT2 235.7 26.4 38.7 10.5 28.5 20.6 28.3 127.7
MMP3 1928.0 751.7 45.7 16.8 22.3 31.1 26.6 2747.4
HSPB7 155.1 888.0 34.5 10.0 58.5 27.8 26.2 442.4
GBP1 267.1 128.0 166.6 12.0 11.3 18.1 19.6 323.4
APOD 478.9 237.6 44.7 6.8 6.2 38.1 17.2 33.6
SERPINB7 524.2 173.5 844.6 6.5 10.2 18.9 17.2 764.6
KRT34 1360.7 68.1 1547.9 5.0 5.0 16.5 17.1 1072.5
CLIC3 114.9 141.9 1304.0 9.6 109.7 18.5 15.5 821.8
SAMD9 341.7 181.8 124.5 22.7 6.2 25.7 15.0 2285.3
PSG6 464.3 63.0 43.4 5.0 33.8 16.4 13.9 437.3
PSG4 570.8 219.9 45.0 13.3 84.8 19.4 12.9 502.3
SYNC1 408.9 411.1 337.8 9.9 10.6 15.0 12.7 411.5
CLEC3B 193.5 364.7 48.0 5.0 5.0 15.7 12.1 87.6
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OSR2 297.6 198.8 46.2 5.0 5.0 15.8 10.5 157.6
PSG9 1015.8 353.7 64.5 5.0 29.6 11.9 7.2 990.1
C10ORF54 534.0 98.2 40.9 5.0 25.7 12.7 5.0 271.7
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4F 48h 4F 72h EDHB 24h EDHB 48h EDHB 72h 4F EDHB 24h4F EDHB 48h4F EDHB 72hHIF KD
34552.3 30845.8 10239.0 8618.1 9170.1 11680.4 11927.1 8835.0 13935.0
1993.8 1498.0 4723.8 4822.2 5372.9 3597.7 4247.3 3760.0 3980.5
5347.0 4543.8 12956.2 12934.5 16977.9 12391.3 12054.2 5189.0 15306.4
1842.6 1376.7 5633.6 5493.8 7764.8 5079.8 3685.0 2224.8 5308.1
7874.2 6038.2 4847.2 4753.1 5021.0 4851.4 5407.1 5930.5 4446.5
15354.8 9176.0 4089.2 8877.2 9705.7 6929.0 9463.7 9802.8 8869.4
1709.9 1672.6 2072.6 4029.1 3241.1 3132.4 2878.9 2968.0 4020.9
3000.2 1720.8 5444.0 3281.4 4480.9 2618.7 3569.9 1611.4 9084.8
962.4 905.0 1186.6 1605.0 1909.9 1025.4 1081.7 803.2 3499.9
1540.6 716.2 1183.0 740.7 1057.4 1182.6 1631.6 912.9 499.8
7554.0 4519.9 4526.8 3847.7 4958.6 4288.2 4522.3 3532.8 6439.3
922.4 906.9 241.9 614.2 538.4 468.3 576.8 361.1 1800.7
6772.5 5725.6 3515.1 2335.3 2605.5 3006.1 5919.8 3802.4 5485.3
1246.2 1303.5 1214.3 1287.2 1623.2 1186.5 1284.2 1140.2 1653.0
3142.1 2231.7 1165.8 1192.2 1814.6 757.7 981.5 889.6 2260.5
3707.3 3704.5 2787.4 1979.3 1500.7 1344.8 1930.2 2689.6 3675.2
615.4 499.3 444.3 454.5 763.9 295.9 365.2 290.3 1473.8
2605.5 2065.4 3786.5 2743.9 3156.6 3078.0 3055.6 2523.4 4981.5
5687.1 4874.7 4621.7 4754.6 4371.4 3887.8 4777.4 4170.1 4187.8
2312.8 1554.3 4425.5 2844.7 2441.7 2322.1 2252.2 2221.2 2361.5
593.1 506.3 960.8 1547.6 1200.5 1353.8 1230.0 1074.6 2607.8
1259.0 972.1 2209.6 1929.2 2029.8 1691.9 1994.6 1747.6 3858.0
2207.5 2170.8 725.6 828.1 748.3 921.5 1169.2 1720.3 760.7
1125.4 948.1 1070.4 1187.9 1144.6 1257.9 1496.9 1326.7 1149.8
836.1 481.3 3515.6 2898.2 3326.4 3651.1 3686.0 2306.3 1847.9
406.4 234.3 1139.3 1613.9 1595.2 1617.5 1854.4 1032.9 2013.6
913.1 353.0 537.5 687.5 1222.7 913.9 871.5 530.7 643.2
1785.1 1701.0 3617.7 5182.9 4547.1 4027.4 4726.7 4874.9 3946.0
1079.5 468.8 3886.8 4006.2 5131.7 3117.6 2240.6 554.7 4864.9
38.6 49.9 325.4 351.4 331.5 200.6 188.3 136.2 501.6
664.3 820.0 509.6 352.6 559.1 556.3 530.7 513.0 721.7
1057.0 1308.6 238.4 975.0 650.7 610.9 1371.5 1520.8 720.5
1047.7 766.3 517.0 579.3 538.7 479.0 456.0 321.0 965.1
803.7 730.2 1021.2 845.3 554.3 914.7 769.0 345.3 2096.8
1147.3 1185.2 218.0 430.9 313.2 572.3 858.1 923.7 775.3
2710.4 2315.4 858.7 2498.4 1164.3 1323.1 1111.2 1628.1 1308.3
248.2 283.7 178.2 173.1 159.7 161.2 208.9 293.2 115.9
282.2 203.8 1138.0 1366.5 1307.9 975.2 898.1 719.3 1271.8
293.5 332.9 683.9 670.4 701.7 685.0 1054.1 1107.5 3011.6
507.6 351.9 725.7 824.6 889.3 778.2 961.4 907.6 1273.0
1303.6 1266.8 1893.6 1283.2 1264.5 1415.1 1333.1 1059.3 1559.1
397.6 358.6 1254.5 1411.3 1094.4 883.7 1171.9 1242.8 1123.7
965.1 773.5 1581.3 1638.2 1074.5 2362.1 2767.0 2044.9 2625.0
500.7 463.5 1457.6 1263.9 1209.9 1035.6 857.0 330.8 1034.6
1847.9 1036.1 789.9 728.7 872.9 842.8 830.7 806.0 676.7
1842.7 1096.9 6225.7 4570.9 3733.6 3220.1 4313.3 5640.8 1527.1
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1980.1 2123.0 1270.1 824.1 863.5 1134.7 1769.3 2452.9 1512.7
200.3 181.5 815.0 535.7 623.0 595.4 436.6 191.0 850.2
948.4 568.6 1098.2 908.1 830.1 728.1 1081.2 977.0 847.4
1401.4 868.8 2753.3 2367.7 3283.8 2320.0 2648.4 1197.5 4721.1
2127.7 2390.1 1464.4 1647.1 2235.9 1701.6 2306.1 3507.8 1410.6
1369.1 1666.0 822.6 598.8 515.4 947.7 1584.5 2136.3 1351.4
859.0 662.1 810.5 1019.3 836.6 1039.4 999.8 838.2 649.6
266.8 182.0 534.7 627.2 770.9 729.5 884.4 569.7 506.0
1895.7 936.2 195.4 315.9 287.8 11365.8 15835.1 13331.8 4781.6
2974.8 2832.4 2483.9 4204.3 3042.4 3222.5 2157.5 1033.6 7861.0
713.9 523.0 445.0 468.3 501.5 300.5 395.5 264.9 630.2
567.9 1359.3 401.4 191.7 220.9 446.8 448.5 635.2 1029.2
936.7 1117.7 794.6 577.7 445.9 826.6 1371.0 1621.5 1458.8
324.8 212.9 833.8 956.3 890.7 776.8 900.6 806.8 1117.9
436.1 299.6 753.2 398.4 468.5 453.5 440.9 260.6 503.7
306.5 412.1 303.2 276.1 180.0 358.4 226.8 240.4 633.1
3804.1 3972.9 1213.3 1643.7 1158.1 1536.5 2078.5 2161.9 833.8
298.2 170.2 339.9 224.8 357.6 466.8 469.8 167.3 605.3
536.5 468.8 1220.3 1120.6 1207.2 1021.4 1073.1 961.0 1648.8
1317.8 1023.2 961.0 1235.2 1000.4 1048.3 1192.8 848.1 1400.4
389.0 332.9 371.9 462.4 332.7 395.7 399.5 403.8 459.9
713.0 627.9 566.0 598.4 564.0 578.6 678.9 734.4 705.8
1405.1 1560.2 1751.2 1009.9 732.3 1151.4 1873.6 2600.8 2088.0
654.3 402.4 340.5 347.8 247.0 539.9 883.4 627.0 1380.7
413.1 285.8 965.7 855.3 914.1 1025.3 1120.3 920.3 1011.0
583.3 444.4 324.2 399.7 432.7 326.3 390.3 383.1 431.8
200.0 174.3 164.1 161.6 195.9 159.2 230.8 119.0 325.5
454.4 1074.0 367.8 171.8 162.0 373.9 356.3 475.9 721.8
846.0 448.4 75.5 187.2 101.8 474.1 1031.4 912.4 457.2
143.3 135.7 167.2 256.7 387.3 138.9 103.2 52.1 368.1
1209.4 1144.4 1335.6 938.3 837.2 670.2 658.3 581.2 2453.2
994.9 792.8 41.4 161.7 132.5 207.2 202.0 60.3 297.3
310.0 247.8 576.9 237.6 870.5 921.9 923.8 954.0 714.3
176.0 73.4 698.7 638.8 758.2 648.2 635.6 448.3 658.3
157.3 154.4 28.9 43.4 45.1 34.3 40.4 29.1 125.5
1497.6 419.4 2032.8 1622.2 1693.0 2350.8 2639.9 2357.0 2522.1
136.8 62.4 466.0 322.9 384.6 417.2 245.4 62.4 542.2
328.5 207.0 78.6 153.9 206.0 858.6 1005.9 640.9 1032.1
78.4 158.2 1680.1 1242.1 849.4 558.3 772.4 1143.1 720.5
408.7 189.7 741.6 849.8 1044.7 928.4 716.3 362.9 570.6
444.3 167.8 5326.0 1788.6 5096.9 3200.5 2824.6 639.4 3219.3
428.3 665.2 68.0 175.3 147.9 225.7 316.3 86.7 210.7
2598.3 1610.9 311.2 396.4 357.7 2241.6 3487.8 3279.9 1119.0
290.4 146.0 203.5 161.4 185.9 163.3 222.4 170.9 266.1
331.4 175.7 539.7 438.0 536.8 424.8 518.7 467.0 632.7
288.8 275.8 152.2 225.9 287.4 267.3 220.8 137.6 659.6
131.5 293.8 51.9 74.5 75.5 57.7 59.2 77.8 115.3
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135.3 138.8 224.2 374.0 287.0 329.3 393.5 264.6 622.4
509.5 249.7 786.9 677.4 847.5 754.9 922.8 672.4 1043.4
639.6 793.7 37.4 83.5 55.3 53.9 81.6 84.8 340.3
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SCR KD
13290.7
4898.7
18392.0
6086.7
4531.3
7051.6
4359.1
6436.2
3411.9
382.5
5403.1
2069.9
8296.7
1995.8
1480.8
4712.5
813.7
6212.9
5112.2
1782.6
1882.5
3064.8
1428.7
1227.0
1824.4
1822.0
514.4
5590.3
5317.8
994.0
1082.4
563.4
1172.9
2552.6
652.6
2877.7
153.2
1768.7
2210.6
1226.9
2636.6
1401.9
2120.4
1956.2
711.9
1712.1
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1194.5
952.5
827.9
3610.9
1567.7
1105.0
632.0
617.9
729.9
7799.9
755.0
915.6
1067.8
1216.6
408.3
1258.9
839.5
553.0
1989.7
1594.6
495.4
643.3
2880.8
791.7
1261.1
420.1
239.4
693.8
204.1
459.4
3063.2
989.1
915.9
518.5
66.7
1153.6
889.2
292.7
663.3
513.0
4036.5
192.1
409.7
353.0
827.5
461.7
106.9
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792.2
1366.6
264.8
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LOG2 ratio PSCs over respective somatic cells LOG2 ratio over FFs
Pathway Gene FFiPSCs DFiPSCs AFiPSCs hESCs 4F 24h
HIF pathway HIF1A -1.32472 -0.14476 -2.12118 -0.33018 -0.24648
HIF2A -1.277 0.254546 -1.86007 -1.828 -0.92826
HIF3A 0 -1.13546 -1.0079 1.314304 1.163173
EGLN1 -0.26675 0.478343 -1.22186 0.86345 0.167642
EGLN2 0.022896 1.667587 -0.05731 1.715912 1.114057
EGLN3 1.906598 1.243785 -0.36449 3.20434 1.727792
Glucose metabolism SLC2A1 0.838216 3.37233 -0.63902 1.871524 -0.38918
SLC2A3 3.161092 3.626333 2.593632 4.471338 -0.43842
SLC2A4 0.134897 -1.75626 -0.68636 1.073538 1.337318
LDHA -1.24821 -0.02246 -1.02373 0.413997 0.956869
LDHB 0.628746 2.743092 0.090048 1.080396 0.501023
LDHC 0 -1.63573 -0.82699 3.544952 2.456882
LDHD 0.552873 1.392309 1.449535 2.97693 0.871806
PFKL 0.425188 1.103037 -0.43161 1.211234 0.339445
PFKFB3 0.814285 1.978096 -0.94773 1.675069 0.532532
PKM2 0.085242 0.751188 -1.08879 0.475667 0.590584
PKLR 0 -1.70998 -0.69799 1.914589 1.808865
PDK1 0.784813 -0.05158 -0.82282 2.652892 1.738163
PDK3 2.023877 3.236353 0.831652 4.456384 0.434946
ENO2 1.037563 2.01967 0.312073 3.221445 -0.08439
ALDH9A1 -0.52749 0.810336 -0.35254 1.29554 0.075207
mTOR/Autophagy BNIP3 -1.23455 0.632964 -0.98902 1.523424 -0.06827
IDH1 0.993386 2.532364 2.035234 3.016112 0.42
REDD1 1.514988 3.078718 2.104921 2.840165 0.19
FRAP1 1.095095 2.114259 0.840836 2.367248 0.64
RICTOR 0.731814 -0.14735 -0.91735 1.556596 1.06
TSC1 -0.29518 1.328942 -0.46117 -0.08845 -0.07
TSC2 1.188298 1.42713 -0.30013 0.937955 -0.05
EIF4B 0.342956 1.912345 1.411853 2.134099 -0.09
LKB1 0.759724 0.849671 -0.56368 0.964241 0.60
ATG5 -0.55435 1.08134 0.224307 1.397168 0.25
ATG7 -0.69998 0.666393 -0.76789 0.784888 1.08
ATG10 0.870945 1.724113 1.012972 3.084164 0.79
ATG12 -0.2937 1.31414 -0.25749 1.569154 0.71
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LOG2 ratio over FFs
4F 48h 4F 72h EDHB 24h EDHB 48h EDHB 72h 4F EDHB 24h 4F EDHB 48h 4F EDHB 72h
-0.38949 -0.67326 -0.39634 -0.43809 -0.04532 -0.50406773 -0.12097651 -1.03524687
-1.2843 -1.16017 0.59213 0.294654 0.279806 0.216882601 -0.02755145 0.128134197
1.283967 1.227399 1.340147 1.668346 2.044068 1.357834604 1.41566349 1.366241071
0.688618 0.395339 0.689773 0.817407 1.337671 0.853578267 1.16068642 0.513313759
1.590191 1.407596 -0.14252 -0.52898 -0.45133 -0.13779387 -0.20269747 -0.18205001
2.178325 2.205649 0.875938 1.640353 1.692109 1.278640207 1.18186458 1.53463737
0.271099 0.214724 -0.3357 -0.50101 -0.04558 -0.29474642 -0.55226665 -0.76993463
-0.14209 0.160589 -0.59201 -0.59818 -0.00459 -0.23783633 0.05951629 -0.20992319
1.470044 1.482445 1.850267 1.563047 2.14463 1.730640825 2.15870283 1.707071503
0.87278 0.521507 0.515879 0.319926 0.61524 0.380431993 0.2305529 0.002761306
1.387434 1.176448 -0.69524 -0.66801 -0.66674 -0.45201987 -0.60491799 -0.61229165
2.208933 2.471894 1.633983 2.231059 2.106531 1.026447397 0.67308817 2.383168443
0 0.766061 0.32238 1.707187 1.600474 1.4896611 0.78809214 1.188007121
0.492777 0.474184 1.188152 0.946982 1.131325 0.911373767 0.96938046 0.91618633
0.978268 0.861875 1.193726 1.070762 1.171731 1.063587487 1.01879591 0.813540497
0.599438 0.163701 1.42983 1.658813 1.462483 1.535814579 1.60359922 1.790236794
1.612614 1.688279 1.659283 1.847028 1.920683 1.451551383 1.8176871 1.765805438
1.721297 1.619517 1.381037 1.78312 1.951815 1.323538461 1.71571916 1.393300736
0.584895 0.215747 1.794389 1.868575 1.962995 1.993684507 1.92576498 1.592561741
0.044764 -0.02124 1.880062 0.696102 1.049519 1.182336225 0.77853425 1.272774798
0.221064 0.136057 0.119773 0.022001 0.341679 0.054686503 0.13760004 0.13757899
0.06712 -0.15464 0.426042 -0.06127 0.954506 0.589615216 0.17958938 -0.11082864
1.115855 1.767397 -0.02526 0.110223 -0.05926 0.742687069 0.88580219 1.131558358
0.753582 2.14973 -0.68675 -0.91987 -1.30265 -0.75639503 -0.63174354 1.042291129
0.57796 0.766775 1.112215 1.111626 1.009241 0.813621373 0.95210913 0.79393086
1.342604 1.03313 1.827893 2.02331 2.126559 2.233730879 2.08670539 1.674324834
0.033172 0.068781 -0.66091 -0.2974 -0.4351 -0.57644638 -0.48441901 -0.2228336
-0.021 -0.12102 1.113446 1.695776 0.999762 0.977921037 0.79208675 1.220387482
0.443335 0.658392 -0.03136 0.073874 0.040324 -0.05730454 -0.14019292 0.098470173
1.052762 1.14325 1.067682 1.423491 0.694329 1.170153203 0.48430684 1.330947419
0.513042 0.658055 -0.38546 -0.55282 -0.19185 -0.32225646 -0.61126102 -0.3129495
1.096352 0.981186 -0.30869 -0.17181 -0.21949 -0.26713564 -0.00075836 0.010926037
0.452965 0.876907 1.079918 0.760891 0.89901 0.973226302 0.57335314 0.82930881
0.848512 0.445102 0.135664 -0.36603 0.208828 0.428855037 0.52201342 0.474980525
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LOG2 ratio over SCR-KD fibroblasts
HIF1-KD
-2.36353
-0.47953
-0.46067
-0.81644
0.323768
-0.59355
-0.43584
-0.87866
0.501852
-0.29101
0.039252
-0.47357
0.017723
-0.31976
0.083061
-0.34047
1.047267
0.045597
-1.048
-1.09335
-0.53001
-0.65086
0.014818
-0.58453
0.133109
-0.83028
0.565405
-0.10668
-0.55512
-0.8339
0.20546
0.1318
-0.03871
0.329465
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Supp. Table 4. List of primers used for real-time QPCR analysis 
 
 
 
Gene Forward sequence (5’-3’) Reverse sequence (5’-3’) 
ACTB TCAAGATCATTGCTCCTCCTGAG ACATCTGCTGGAAGGTGGACA 
PDK1 ACTTCGGATCAGTGAATGCTTG ACTCTTGCCGCAGAAACATAAA 
PDK3 CGCTCTCCATCAAACAATTCCT CCACTGAAGGGCGGTTAAGTA 
PKM2 AAGGACCTGAGATCCGAACTG GCGTTATCCAGCGTGATTTTGA 
HIF1A GGCGCGAACGACAAGAAAAAG CCTTATCAAGATGCGAACTCACA 
HIF2A CTCTCCTCAGTTTGCTCTGAAAA GACAGAAAGATCATGTCGCCA 
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